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ABSTRACT
The long-term effects of stroke often include cognitive impairments, but other
than cognitive rehabilitation, which is often not fully successful, there is no intervention
to treat cognitive impairments in stroke survivors. Our laboratory has previously shown
that immunotherapy directed against the Nogo-A protein, which is enriched on
oligodendrocytes, improves recovery of skilled forelimb sensorimotor function in adult
and aged rats after an ischemic stroke lesion to the sensorimotor cortex. Furthermore, this
recovery was correlated with axonal sprouting from intact pathways to denervated areas,
as well as dendritic sprouting and increased dendritic spine density in the contralateral
sensorimotor cortex. In the present project we aimed to investigate whether anti-Nogo-A
immunotherapy improves performance on a spatial memory task after a sensorimotor
cortical stroke in aged rats. We found that rats with ischemic stroke and treated with antiNogo-A immunotherapy performed better on the reference memory portion of the Morris
water maze than control antibody treated rats. In the hippocampus, a brain area important
for spatial memory, we found a decrease in dendritic complexity on the same side as the
stroke when compared to normal aged rats. However, anti-Nogo-A immunotherapy did
not prevent this decrease in dendritic complexity in the hippocampus on the same side as
the stroke lesion. To further investigate whether Nogo-A plays a role in dendritic
structural plasticity, and specifically the Nogo-A found in neurons, we used RNA
interference to reduce the levels of Nogo-A in hippocampal CA1 pyramidal cells in aged
xiv

rats. We did not detect any changes in dendritic spine density and morphology. Taken
together this suggests that anti-Nogo-A immunotherapy may be a successful treatment for
cognitive impairments caused by stroke, although the potential neuroanatomical basis for
this recovery is still under investigation.
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CHAPTER ONE
OVERVIEW AND HYPOTHESIS
Each year in the United States 795,000 people have a new or recurrent stroke
(Lloyd-Jones et al., 2009). In ischemic stroke survivors over the age of 65, nearly 50%
have cognitive deficits six months post-stroke (Kelly-Hayes et al., 2003). Furthermore,
stroke patients without dementia at a baseline evaluation had a faster decline in memory
performance as compared to aged individuals without stroke (Reitz et al., 2006).
Cognitive rehabilitation is currently the only treatment for the long-term cognitive
impairments caused by stroke and is often not successful. With the burdens that cognitive
impairment places on survivors of stroke and their care-givers, it is important to develop
new treatments for cognitive impairments after stroke.
A promising novel treatment for stroke is anti-Nogo-A immunotherapy, which is
directed against Nogo-A, the myelin associated inhibitor of axonal growth (Gonzenbach
et al., 2008). After sensorimotor cortical stroke in adult and aged rats anti-Nogo-A
immunotherapy given one week later improved performance on a skilled forelimb
reaching task (Papadopoulos et al., 2002a; Markus et al., 2005b; Seymour et al., 2005a;
Tsai et al., 2007). The improved performance was correlated in adult rats with axonal
sprouting across the midline from intact pathways to denervated areas (Papadopoulos et
al., 2002a; Seymour et al., 2005a), and with dendritic sprouting and increased dendritic
spine density in the contralesional sensorimotor cortex (Papadopoulos et al., 2006).
1
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Anti-Nogo-A immunotherapy has been shown to improve cognitive performance
on a spatial memory task after traumatic brain injury in adult rats (Lenzlinger et al.,
2005b; Marklund et al., 2007a), and to induce recovery from severe neglect caused by a
cortical lesion (Brenneman et al., 2008b). Whether anti-Nogo-A immunotherapy
improves cognitive performance in aged rats after a stroke has not yet been investigated.
Additionally, the role that Nogo-A plays in dendritic structural plasticity in the aged
hippocampus, an area important for spatial memory, has not yet been investigated.

HYPOTHESIS
Neutralizing the Nogo-A protein will improve memory performance after stroke in
the aged by enhancing neuronal plasticity.

Specific Aim 1: Determine whether anti-Nogo-A immunotherapy will improve
performance on a spatial memory task after stroke in the aged. Aged rats will be
tested on the Morris water maze after stroke and intracerebroventricular treatment with
anti-Nogo-A immunotherapy or a control antibody.

Specific Aim 2: Determine whether anti-Nogo-A immunotherapy will induce
dendritic plasticity in the hippocampus after stroke in the aged. The brains from the
animals from aim 1 will be processed for Golgi-Cox staining, and CA3 and CA1
pyramidal neurons, and dentate gyrus neurons will be analyzed for dendritic complexity
and dendritic spine density and morphology.

3
Specific Aim 3: Determine whether knockdown of neuronal Nogo-A will induce
structural changes in dendritic spines in the hippocampus of aged rats. Aged rats
will be injected with either a control virus carrying the EGFP reporter transgene, or a
virus carrying genes for a small hairpin RNA (shRNA) directed against Nogo-A and
EGFP, and four weeks later CA1 pyramidal cells will be analyzed for dendritic spine
density and morphology.

CHAPTER TWO
REVIEW OF LITERATURE
NEURONAL PLASTICITY IN THE DEVELOPING AND ADULT CNS
Kennard Principle
In the 1930’s Margaret Kennard showed that non-human primates given motor
cortical injury during development had better functional recovery than monkeys given
motor cortical injury as adults (Kennard, 1936, 1938). The idea that there is improved
recovery from CNS damage in the young as compared to adults became known as the
“Kennard Principle,” though recovery in the young after CNS damage seems to depend
upon the location and age (Schneider, 1979; Kolb et al., 1989). Improved functional
recovery in the young after CNS damage seems to be based upon neuroanatomical
plasticity, or changes in the structure of dendrites and axons (Kolb and Whishaw, 1989).
For example, after unilateral sensorimotor cortical lesions in neonatal rats axons from the
intact corticospinal tract sprouted across the midline to innervate denervated areas, and
these axons were functionally connected to the intact hemisphere (Kartje-Tillotson et al.,
1987; Barth et al., 1990). Neuronal plasticity does occur in the adult CNS, but it is very
limited (Cotman et al., 1981; Darian-Smith et al., 1995; Goldman et al., 1997; Bareyre et
al., 2004; Schaechter et al., 2006).
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GROWTH INHIBITORY ENVIRONMENT OF THE ADULT CNS
The Discovery of Nogo-A
After injury to the adult CNS axons are unable to regenerate or sprout more than a
couple of mm, but after injury to the adult peripheral nervous system (PNS) axons grow
long distances (Davies et al., 1996). In a landmark experiment, Aguayo and his colleague
took a segment of sciatic nerve from a rat and positioned one end of the graft at the
medulla and the other end at the thoracic spinal cord. After 5.5-7.5 months the rats were
sacrificed, and axons of brain stem and spinal cord neurons were found to have grown
more than 30 millimeters into the sciatic nerve graft (David et al., 1981). This experiment
suggested that the environment of the PNS allows for axonal growth, while the
environment of the CNS does not. The lack of axonal growth in the CNS as opposed to
the PNS could be due to differences in availability of trophic factors, or to a nonpermissive substrate in the CNS. To differentiate between these possibilities, Schwab et
al. cultured neurons in the center of a three-compartment chamber in the presence of
nerve growth factor (NGF) with a sciatic nerve segment extending from the center to one
side chamber and a optic nerve segment extending from the center to the other side
chamber. After 10 to 20 days in culture axons were found extending through the sciatic
nerve and entering the side chamber, but no axons were found in the optic nerve, and the
same results were shown even when the nerve segments were dead (Schwab et al., 1985).
This experiment suggests that the lack of axonal growth in the CNS is due to a nonpermissive substrate rather than a lack of trophic factors, because axons did not grow into
the optic nerve segment even with the presence of nerve growth factor.

6
Schwab and his colleagues went on to show that differentiated oligodendrocytes
and spinal cord myelin, but not astrocytes and immature oligodendrocytes, are nonpermissive for neurite growth and fibroblast spreading (Schwab et al., 1988). Next they
isolated 35- and 250-kD membrane bound proteins (NI-35/250) from rat myelin that are
non-permissive for neurite growth and fibroblast spreading (Caroni et al., 1988c). The
IN-1 monoclonal antibody raised against the NI-35 and NI-250 proteins in part
neutralized the non-permissive properties of CNS myelin for neurite growth and
fibroblast spreading in vitro (Caroni et al., 1988a).
A bovine homologue of NI-250 called bNI-220 was isolated and it was found that
the IN-1 monoclonal antibody in part neutralized the neurite growth and fibroblast
spreading properties of bNI-220 (Spillmann et al., 1998). Six peptide sequences were
obtained during the purification of bNI-220, and from this information in 2000 the gene
encoding NI-220/250 was cloned independently by three groups and named Nogo-A
(Chen et al., 2000b; GrandPre et al., 2000; Prinjha et al., 2000).

The Signaling Pathway of Nogo-A
Three splice variants, Nogo-A, -B, and –C, are produced from the Nogo gene by
alternative splicing and alternate promoter usage (Chen et al., 2000b; GrandPre et al.,
2000; Prinjha et al., 2000). Nogo-A has three active sites as follows: a Nogo-A/-B Nterminal region that inhibits fibroblast spreading; a Nogo-A specific region that inhibits
neurite outgrowth, induces growth cone collapse, and inhibits fibroblast spreading; and a
C-terminal region, Nogo-66, common to all three is forms that induces growth cone
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collapse (Oertle et al., 2003). Nogo-A is an integral membrane protein that has a di-lysine
endoplasmic reticulum retention signal at the C terminus but no signal sequence at the Nterminus (Chen et al., 2000b; GrandPre et al., 2000; Prinjha et al., 2000). Nogo-A is
highly enriched in the endoplasmic reticulum, but is also found in the cell membrane with
all three active sites exposed to the extracellular space (GrandPre et al., 2000; Dodd et al.,
2005).
Additional molecules contribute to the growth inhibitory environment of the adult
CNS, including chondroitin sulfate proteoglycans (Niederost et al., 1999; Schmalfeldt et
al., 2000), myelin-associated glycoprotein (MAG, McKerracher et al., 1994;
Mukhopadhyay et al., 1994), oligodendrocyte and myelin glycoprotein (OMgp, Wang et
al., 2002b), and the repulsive axon guidance molecules Ephrin B3 (Benson et al., 2005),
and Semaphorin 4D (Moreau-Fauvarque et al., 2003). With the exception of the
chondroitin sulfate proteoglycans, which are extracellular matrix molecules, all of these
growth inhibitory molecules can be found in myelin (Yiu et al., 2006). The CNS of adult
higher vertebrates loses the capacity to regenerate concurrently with the onset of
myelination (Ferretti et al., 2003). This suggests the importance of myelin proteins in
inhibiting neuronal plasticity and regeneration in the CNS.
A common receptor was identified called the Nogo-66 receptor (NgR1) that
bound to the Nogo-66 domain common to all three isoforms of Nogo, along with MAG,
and OMgp (Fournier et al., 2001; Domeniconi et al., 2002; Wang et al., 2002b). With
this discovery it was hypothesized that myelin growth inhibitors converged on the NgR1
to inhibit growth (Fig 1, Giger et al., 2008). However, evidence has revealed that it is
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more likely that myelin growth inhibitors signal through multiple receptor systems, and
the contribution of each receptor system may vary depending upon the type of neuron
(Giger et al., 2008). Indeed an additional receptor called paired immunoglobulin-like
receptor B (PirB) has been found to bind Nogo-66, MAG and OMgp to inhibit neurite
outgrowth (Atwal et al., 2008).
The NgR1 contains eight leucine rich repeat domains, and is linked to the
membrane by a glycosylphosphatidyl inositol (GPI) anchor (Fournier et al., 2001). The
NgR1 does not cross the membrane so it requires co-receptors for signal transduction.
Several co-receptor molecules have been identified, including p75 (Wang et al., 2002a)
and TROY (Park et al., 2005), members of the tumor necrosis factor receptor (TNFR)
family, and LINGO-1 (Mi et al., 2004).
Several pathways have been identified in the intracellular signaling of myelin
inhibitors (Fig 1). First, Nogo-A and MAG activate the small GTPase RhoA (Lehmann et
al., 1999; Niederost et al., 2002; Fournier et al., 2003) by releasing it from the inhibitory
regulator Rho-guanine dissociation inhibitor (Rho-GDI, Yamashita et al., 2003). RhoA
activates Rho Kinase (ROCK), and it is thought that ROCK activates Lin-11, Isl-1, Mec3 Kinase 1 (LIMK1) by phosphorylation (Hsieh et al., 2006). The activated LIMK1 then
phosphorylates and inactivates cofilin, an actin depolymerization factor (Hsieh et al.,
2006). Secondly, Nogo and MAG cause an increase in intracellular calcium (Bandtlow et
al., 1993; Wong et al., 2002; Hasegawa et al., 2004) and activation of Protein Kinase C
(PKC, Hasegawa et al., 2004; Sivasankaran et al., 2004). Finally, NgR1 activation also
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leads to phosphorylation and transactivation of the epidermal growth factor receptor
(EGFR) by calcium signaling (Koprivica et al., 2005).
Interestingly, it has been demonstrated that the Nogo-A specific region, also
known as the Amino-Nogo domain, can regulate RhoA independent of the NgR1/p75
pathway, suggesting that the Nogo-A specific region has a distinct binding site
(Schweigreiter et al., 2004). Recently it was found that the Amino-Nogo domain of
Nogo-A may inhibit integrin signaling to inhibit neurite growth (Hu et al., 2008).
Analysis of gene and protein changes after Nogo-A neutralization gives further
insight into Nogo-A signaling. In rat hippocampal slice cultures the anti-Nogo-A
antibodies 11C7 and 7B12 cause changes in RNA transcripts for genes related to growth,
including genes function in the extracellular matrix, cell adhesion, neurogenesis, GTPase
signal transduction, and growth factors (Craveiro et al., 2008b). In genetically modified
mice lacking Nogo-A samples from unlesioned spinal cords showed changes in protein
expression in proteins related to the cytoskeleton, signaling, neuroprotection, metabolism
and transport as compared to wild-type mice (Montani et al., 2009).
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Signaling Pathways of Myelin Inhibitors
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Figure 1. Signaling Pathways of Myelin Inhibitors.
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ANTI-NOGO-A IMMUNOTHERAPY, AND OTHER METHODS TO
NEUTRALIZE NOGO-A, ENHANCE FUNCTIONAL RECOVERY AND
NEURONAL PLASTICITY AND REGENERATION AFTER CNS INJURY
Cortical Lesions, Stroke and Traumatic Brain Injury in Rodents
In the 1990’s Schwab and his colleagues showed that the IN-1 anti-Nogo-A
antibody induced functional recovery, axonal regeneration, and axonal plasticity after
lesion to the corticospinal tract at the level of the spinal cord or the medullary pyramid
(Schnell et al., 1990, 1993; Bregman et al., 1995; Thallmair et al., 1998; Z'Graggen et al.,
1998). The corticospinal tract originates from layer V pyramidal cells in the sensorimotor
cortex, so a logical next step was to examine whether anti-Nogo-A antibodies would
enhance functional recovery and neuronal plasticity after lesions to the sensorimotor
cortex. Indeed, when adult rats underwent a sensorimotor cortical aspiration lesion and
treatment with the IN-1 anti-Nogo-A antibody, they had improved performance on a
skilled forelimb reaching task and on a skilled forelimb walking test as compared to
control antibody treated rats (Emerick et al., 2003; Emerick et al., 2004). This behavioral
recovery became statistically significant 4 weeks after the sensorimotor cortical lesion
and antibody treatment. The functional recovery was correlated with neuronal plasticity
in the intact corticospinal tract, in which fibers were found to have sprouted across the
midline into denervated areas at the level of the spinal cord, red nucleus and basilar
pontine nuclei (Fig 2, Wenk et al., 1999; Emerick and Kartje, 2004). In addition, after
sensorimotor cortical lesion and treatment with the anti-Nogo-A antibody the intact
cortex sent more projections to the contralateral striatum as compared to control antibody
treated rats (Fig 2, Kartje et al., 1999). The neuronal plasticity in projections from the
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intact sensorimotor cortex was shown to be functional, because intracortical
microstimulation of the intact cortex caused increased ipsilateral forelimb movements as
compared to control antibody treated rats (Emerick et al., 2003).
In the more physiologically relevant model of stroke, adult rats underwent a
middle cerebral artery occlusion (MCAO) that resulted in an ischemic stroke in the
sensorimotor cortex and were treated with the IN-1 anti-Nogo-A antibody. These animals
also had improved performance on a skilled forelimb reaching task as compared to
control antibody treated rats (Papadopoulos et al., 2002a). In this experiment behavioral
recovery became statistically significant at 6 weeks after the MCAO and antibody
treatment.
In these studies of cortical aspiration lesion and MCAO, the anti-Nogo-A
antibody treatment was given starting at the same time as the lesion. However, in the
clinical setting it would be advantageous for a stroke treatment to be effective when given
after a CNS insult. Therefore, studies were undertaken to evaluate anti-Nogo-A
immunotherapy as a delayed treatment for stroke, and it was found that the anti-Nogo-A
antibodies were effective up to one week after stroke in inducing functional recovery in
skilled forelimb reaching in adult rats (Wiessner et al., 2003b; Seymour et al., 2005b).
Experiments were also undertaken to evaluate more clinically relevant delivery routes.
Initial studies on treatment of stroke with anti-Nogo-A immunotherapy used hybridoma
cells secreting the IN-1 antibody (Papadopoulos et al., 2002b; Seymour et al., 2005b),
and then researchers began to use mini-osmotic pumps to deliver purified monoclonal
anti-Nogo-A antibodies intracerebroventricularly (Wiessner et al., 2003b; Markus et al.,
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2005b). More recently it has been shown that intrathecal delivery is also effective in
enhancing functional recovery in adult rats after stroke (Tsai et al., 2007).
Similar to the neuronal plasticity after sensorimotor cortical aspiration lesion and
treatment with anti-Nogo-A immunotherapy, after stroke in adult rats and treatment with
anti-Nogo-A immunotherapy fibers from the intact corticospinal tract were found to have
sprouted across the midline into denervated areas at the level of the spinal cord and the
red nucleus (Fig 2, Papadopoulos et al., 2002b; Wiessner et al., 2003b; Seymour et al.,
2005b). Additionally, after stroke in adult rats and treatment with anti-Nogo-A
immunotherapy thalamic activation was reported as increased as indicated by functional
magnetic resonance imaging (fMRI) after stimulation of the impaired forepaw as
compared to control antibody treated rats (Markus et al., 2005b). In addition to this
reported axonal plasticity, dendritic plasticity has also been shown after stroke and
treatment with anti-Nogo-A immunotherapy. Layer V pyramidal neurons in the
contralesional sensorimotor cortex had increased dendritic branching, dendritic arbor
length, and dendritic spine density after MCAO and anti-Nogo-A immunotherapy (Fig 2,
Papadopoulos et al., 2006). Two additional important observations were made in this
study. First, treatment of unlesioned adult animals with the anti-Nogo-A antibody caused
a transient increase in dendritic complexity in layer II/III neurons in the occipital cortex,
and layer V pyramidal neurons of the sensorimotor cortex at two weeks, but by six weeks
the dendritic arbors had returned to baseline levels. Secondly, in animals with a stroke,
lasting increases in dendritic arbor complexity after anti-Nogo-A immunotherapy were
specific to the contralesional sensorimotor cortex, because layer II/III neurons in the
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occipital cortex showed no changes in dendritic complexity six weeks after stroke and
anti-Nogo-A immunotherapy. Due to the correlation of neuroanatomical changes and
behavioral results it is thought that axonal and dendritic reorganization of the brain is
responsible at least in part for the improved functional recovery after cortical injury and
treatment with anti-Nogo-A immunotherapy.
Several other methods have been used to manipulate Nogo-A signaling in studies
of experimental stroke. First, mice genetically modified to lack the NgR1 or Nogo-A and
Nogo-B have improved performance on a skilled reaching task after a stroke lesion, and
increased fiber sprouting from intact pathways across the midline into denervated areas at
the level of the spinal cord and red nucleus (Lee et al., 2004). Secondly, rats treated with
the NgR(310)Ecto-Fc protein one week after stroke, which binds to the ligands of the
NgR1 and thereby blocks receptor activation, had improved performance on a skilled
reaching task and increased fiber sprouting from intact pathways across the midline into
denervated areas at the level of the spinal cord and red nucleus (Lee et al., 2004).
Stroke is more prevalent in the aged human population (Lloyd-Jones et al., 2009)
so preclinical studies on potential treatments for stroke should include aged animal
subjects (1999; Grotta et al., 2008). Therefore, aged rats underwent MCAO and were
treated with anti-Nogo-A immunotherapy beginning one week post-stroke. These rats had
improved functional recovery on a skilled forelimb reaching task (Markus et al., 2005b).
However, in this experiment behavioral recovery became statistically significant at 9
weeks after the MCAO, which was a longer time period for recovery as compared to
adult rats with stroke and anti-Nogo-A immunotherapy.
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Another clinically relevant brain injury model in which anti-Nogo-A
immunotherapy has been tested is traumatic brain injury. Adult rats underwent a left
lateral fluid percussion brain injury and 24 hours later treatment with anti-Nogo-A
immunotherapy or a control antibody. The composite neuroscore, a test of motor
function, showed a lesion induced deficit, but there was no difference between the antiNogo-A antibody treated rats and the control antibody treated rats (Lenzlinger et al.,
2005b; Marklund et al., 2007a). Four weeks after the traumatic brain injury rats were
tested on the Morris water maze place task for spatial memory, and rats treated with the
anti-Nogo-A antibody performed better than the control antibody treated rats (Lenzlinger
et al., 2005b; Marklund et al., 2007a). After completion of the place task, rats were tested
on a probe trial and again the rats with traumatic brain injury and treated with the antiNogo-A antibody performed better than the control antibody treated rats (Marklund et al.,
2007a). In addition, rats with traumatic brain injury and treated with the anti-Nogo-A
antibody had higher growth-associated protein-43 (GAP-43) expression, an axonal
growth marker, in CA1 of the hippocampus than control antibody treated rats (Marklund
et al., 2007a).
Anti-Nogo-A immunotherapy has also been tested in a cortical injury model
causing severe neglect. Rats underwent aspiration of the medial agranular cortex and
immediately delivery of anti-Nogo-A immunotherapy or a control antibody was started
(Brenneman et al., 2008b). Lesioned animals exhibited contralesional neglect to visual,
tactile and auditory stimuli. Lesioned animals treated with anti-Nogo-A immunotherapy
recovered from the neglect more quickly and more completely than control antibody
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treated rats. Additionally, after knife cut surgery to sever the corpus collosum, the
recovered anti-Nogo-A antibody treated rats once again exhibited neglect, suggesting that
the contralesional hemisphere was involved in the initial recovery.
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Neuronal Plasticity after Sensorimotor Cortical Lesion and Anti-Nogo-A
Immunotherapy

Red Nucleus

Basilar Pontine
Nuclei

Spinal Cord

Figure 2. Neuronal Plasticity after Sensorimotor Cortical Lesion and Anti-Nogo-A
Immunotherapy. The intact corticospinal tract sprouts across the midline into
denervated areas at the level of the red nucleus, basilar pontine nuclei and spinal cord.
Layer V pyramidal neurons in the intact sensorimotor cortex have increased dendritic
branching, and dendritic arbor length. The intact cortex sends more projections to the
contralateral striatum. Axonal and dendritic sprouting are shown in red.

18
Pyramidotomy and Spinal Cord Injury in Rodents and Primates
At the same time that anti-Nogo-A immunotherapy was being evaluated for the
treatment of cortical injury and stroke it was also being evaluated for the treatment of
spinal cord injury using several models.
In the first model, dorsal hemisection, the spinal cord is cut dorsally so that the
dorsal columns and most of the corticospinal tract are severed. When rats underwent a
mid-thoracic dorsal hemisection and were treated with anti-Nogo-A immunotherapy, they
showed improved performance on reflex and motor function tests as compared to control
antibody treated rats (Bregman et al., 1995; Merkler et al., 2001; Liebscher et al., 2005).
This recovery was correlated with regeneration of cut axons though spared tissue bridges
and past the lesion site (Schnell and Schwab, 1990, 1993; Bregman et al., 1995). Similar
axon regeneration is seen after dorsal hemisection in rats and treatment with a Fab
fragment (IN-1 Fab) with the variable domains of the anti-Nogo-A antibody IN-1
(Brosamle et al., 2000). In control antibody treated rats the cut axons regenerated less
than 1 millimeter past the lesion, while in anti-Nogo-A antibody treated rats the cut axons
regenerated up to 11 millimeters past the lesion (Schnell and Schwab, 1990). When the
hindlimb was administered sensory stimulation, the anti-Nogo-A antibody treated rats,
but not the control antibody treated rats, showed cortical activation as measured by blood
oxygenation level dependent (BOLD) fMRI (Liebscher et al., 2005). Raphespinal
(serotonergic) and coeruleospinal (noradrenergic) axons were also shown to have
increased sprouting or regeneration caudal to the lesion as compared to control antibody
treated rats (Bregman et al., 1995).
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Similar recovery of motor function and axonal regeneration after dorsal
hemisection has been demonstrated after treatment with a competitive antagonist of the
NgR1, the Nogo-66 (1-40) antagonist peptide (NEP1-40, GrandPre et al., 2002; Li et al.,
2003), and NgR(310)ecto-Fc protein (Li et al., 2004; Li et al., 2005b). Blocking the
binding between NgR1 and its co-receptor LINGO-1 with the LINGO-1-Fc after dorsal
hemisection also improves functional recovery and enhances axon regeneration (Ji et al.,
2006). In another approach, blocking the intracellular signal molecules downstream of
Nogo-A, including RhoA with C3 transferase and ROCK with Y-27632, after dorsal
hemisection also leads to improved functional recovery and enhanced axonal
regeneration (Dergham et al., 2002; Fournier et al., 2003).
Studies with non-human primates have further supported the effectiveness of antiNogo-A immunotherapy for the treatment of spinal cord injury. Adult Macaque monkeys
underwent unilateral lesion of the spinal cord at the C7-C8 border and then were treated
with anti-Nogo-A immunotherapy or a control antibody. Monkeys with anti-Nogo-A
immunotherapy recovered ipsilesional hand manual dexterity as measured by the
modified Brickman board task more quickly and to a greater extent than control antibody
treated monkeys (Freund et al., 2006; Freund et al., 2009). Additionally, the monkeys
with anti-Nogo-A immunotherapy recovered ipsilesional capacity to generate force with
the digits as measured by the reach and grasp drawer test faster than control antibody
treated monkeys (Freund et al., 2006). This recovery was correlated with increased
regeneration and sprouting of corticospinal tract neurons both rostral and caudal to the
lesion (Freund et al., 2006; Freund et al., 2007a). However, the anti-Nogo-A
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immunotherapy did not prevent shrinkage and loss of neurons in the contralesional
magnocellular part of the red nucleus (Wannier-Morino et al., 2008), nor the shrinkage of
neurons in the affected motor cortex (Beaud et al., 2008). Sprouting and regeneration of
corticospinal neurons after anti-Nogo-A immunotherapy has also been shown in
Marmoset monkeys after midthoracic unilateral lesion of the spinal cord (Fouad et al.,
2004).
Genetically modified mice that lack Nogo-A, Nogo-A and -B, or Nogo-A, -B, and
–C have also been evaluated after spinal cord injury for functional recovery and axonal
regeneration and sprouting. The results from these studies have been conflicting, most
likely due to different lesion models (Cafferty et al., 2006), different genetic backgrounds
of the mice (Dimou et al., 2006), and compensatory upregulation of Nogo-B (Simonen et
al., 2003). After dorsal hemisection, Nogo-A knockout mice showed enhanced axonal
regeneration (Simonen et al., 2003). After dorsal hemisection, Nogo-A and –B knockout
mice showed improved motor recovery and enhanced axonal regeneration in one study
(Kim et al., 2003) and no enhanced axonal regeneration in another study (Zheng et al.,
2003). After dorsal hemisection, Nogo-A, -B, and –C knockout mice showed no
enhanced axonal regeneration (Zheng et al., 2003). Further experiments are needed to
determine the basis of these conflicting results.
Another model that was used to evaluate anti-Nogo-A immunotherapy for the
treatment of spinal cord injury was pyramidotomy. Pyramidotomy involves surgically
severing the corticospinal tract at the level of the medullary pyramids. Pyramidotomy
allows for unilateral lesion by using the basilar artery as a landmark, and also largely
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spares other descending and ascending systems (Thallmair et al., 1998). After a unilateral
pyramidotomy and treatment with the anti-Nogo-A antibody IN-1, rats showed improved
performance on a skilled forelimb reaching task, a grip strength test, the grid walking
task, and a sensory test as compared to control antibody treated rats (Thallmair et al.,
1998; Z'Graggen et al., 1998). This recovery was correlated with neuronal plasticity with
fibers from the affected corticospinal tract being found to have sprouted across the
midline at the level of the red nucleus and basilar pontine nuclei (Thallmair et al., 1998;
Z'Graggen et al., 1998). At the level of the basilar pontine nuclei these sprouting fibers
made asymmetric synaptic contacts (Blochlinger et al., 2001). Fibers from the spared
corticospinal tract were found to have sprouted across the midline at the level of the
spinal cord into denervated areas (Thallmair et al., 1998). The lesioned corticospinal tract
also was found to regenerate to innervate the dorsal column nuclei (Thallmair et al.,
1998).
Similar results have been shown in genetically modified mice that lack the NgR1
or Nogo-A and Nogo-B. After unilateral pyramidotomy these mice showed improved
performance on a skilled forelimb reaching task and increased fiber sprouting from the
intact corticospinal tract across the midline into the denervated spinal cord as compared
to wild-type mice (Cafferty and Strittmatter, 2006). It is important to note that this same
corticospinal tract fiber sprouting was not observed after dorsal hemisection in NgR1
knockout mice (Kim et al., 2004; Zheng et al., 2005) and in one study in Nogo-A, -B
knockout mice (Zheng et al., 2003). However, after dorsal hemisection in NgR1 knockout
mice there is improved motor function and sprouting of rubrospinal and raphespinal
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axons (Kim et al., 2004). Therefore, the results from genetic neutralization of the NgR1
and Nogo-A and –B appear to be dependent on the lesion model, pyramidotomy vs.
dorsal hemisection, and fiber systems studied.
When rats underwent bilateral pyramidotomy and were treated with the antiNogo-A antibody IN-1, they also showed improved performance on a skilled forelimb
reaching task as compared to control antibody treated rats (Raineteau et al., 2001). In
these rats the unlesioned rubrospinal tract sprouted to increase its innervation of the
spinal cord. Additionally, the sensorimotor cortex was functionally reconnected because
stimulation of the sensorimotor cortex elicited electromyogram (EMG) responses in the
trunk, shoulder, biceps and in some cases the proximal and medial muscles of the
forelimb in rats with pyramidotomy and treated with the anti-Nogo-A antibody, but not in
rats treated with a control antibody (Raineteau et al., 2001).

Axon Regeneration after Nogo-A Neutralization is Not Limited to Descending Pathways
Axonal regeneration is well described after spinal cord injury and treatment with
anti-Nogo-A immunotherapy, but it has also been described within the neocortex,
hippocampus and cranial nerves.
There are two reports of axonal regeneration after anti-Nogo-A immunotherapy in
cholinergic fibers. In the first, adult rats underwent aspiration lesions to the sensorimotor
cortex, transplantation of fetal neocortical tissue into the lesion site and treatment with
either an anti-Nogo-A antibody or a control antibody. Three months later the grafts were
analyzed for the ingrowth of host cholinergic fibers, and rats treated with the anti-Nogo-

23
A antibody had more axonal regeneration/sprouting of cholinergic fibers into the
transplant than control antibody treated rats (Schulz et al., 1998). Therefore, anti-Nogo-A
immunotherapy enhanced the connectivity between the host neocortical tissue and the
fetal neocortical graft. In the second report, 3 week old rats underwent unilateral
aspiration of the dorsal fornix and fimbria to lesion the septohippocampal pathway. At
the time of the septohippocampal lesion a bridge was placed between the septum and
rostral hippocampus consisting of a nitrocellulose strip and human placental extracellular
matrix material soaked in NGF. In control antibody treated rats cholinergic fibers only
regenerated 0.2-1 millimeter into the hippocampus, while in anti-Nogo-A antibody
treated rats cholinergic fibers regenerated 2-4 millimeters into the hippocampus.
Furthermore, the regenerated axons grew into sites corresponding to their original
innervation pattern (Cadelli et al., 1991b).
There have been two reports of axonal regeneration in hippocampal slice cultures
after treatment with an anti-Nogo-A antibody. In the first report, the perforant pathway
was severed in mice hippocampal slice cultures and then the cultures were treated with an
anti-Nogo-A antibody or control antibody. In cultures treated with the anti-Nogo-A
antibody after 7-10 days there were more entorhinal axons growing into the hippocampus
than in cultures treated with control antibody. However, the axons did not grow only into
their original innervation locations, but also grew into ectopic hippocampal layers
(Mingorance et al., 2004a). In the second report, the Schaffer collaterals were severed in
rat hippocampal slice cultures and then the cultures were treated with an anti-Nogo-A
antibody or control antibody. In cultures treated with anti-Nogo-A antibody after 5 days
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there were more axons growing across the lesion than in cultures treated with control
antibody. Additionally, stimulation of CA3 generated higher amplitude evoked potentials
recorded in CA1 in cultures treated with anti-Nogo-A antibody as compared to cultures
treated with control antibody. Interestingly, this study also observed axonal
growth/sprouting in intact hippocampal slice cultures after treatment with an anti-Nogo-A
antibody, but no dendritic growth/sprouting (Craveiro et al., 2008b).
In cranial nerves there have been several reports of axonal regeneration after
Nogo-A neutralization. After the optic nerve is lesioned in rats by freeze-crush, treatment
with an anti-Nogo-A antibody in the presence of fibroblast growth factor (FGF) enhances
axonal regeneration past the lesion as compared to a control antibody (Weibel et al.,
1994). In another approach, the optic nerve was crushed in rats overexpressing the NgR1
or expressing a dominant negative form of NgR1 and at the same time the lens was
injured to stimulate macrophages to release factors favorable to axon regeneration. Rats
overexpressing the NgR1 had impaired axon regeneration, while rats expressing a
dominant negative form of NgR1 had enhanced axon regeneration (Fischer et al., 2004).
In another study, the cochlear nerve was cut in rats between the brain stem and the
internal acoustic meatus. In this model treatment with a Fab fragment (IN-1 Fab) with the
variable domains of the anti-Nogo-A antibody IN-1 enhanced axonal regeneration past
the lesion as compared to control antibody. Additionally, rats treated with IN-1 Fab
showed functional recovery as measured by Brainstem Auditory Evoked Potentials
(BAEP), while animals treated with the control antibody did not recover (Tatagiba et al.,
2002).
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Anti-Nogo-A Immunotherapy Distribution and Mechanism of Action after
Intracerebroventricular Infusion
Commonly used antibodies against Nogo-A include the monoclonal antibody IN1 which recognizes Amino-Nogo, and the more specific monoclonal antibodies 11C7 and
7B12 which recognize short amino acid sequences in Amino-Nogo (Fig 3). When the
11C7 and 7B12 anti-Nogo-A antibodies are infused into the lateral ventricle or
intrathecally in non-lesioned rats or in rats with spinal cord injury or stroke, the
antibodies reach the entire spinal cord and brain including the hippocampus.
Additionally, the anti-Nogo-A antibodies are at high levels near spinal cord lesions or
stroke lesions. Anti-Nogo-A immunotherapy binds to surface Nogo-A on neurons and
oligodendrocytes and causes internalization and degradation of Nogo-A. Indeed, after 7
days of intrathecal infusion of anti-Nogo-A antibodies, the levels of Nogo-A in the spinal
cord were reduced (Weinmann et al., 2006). Therefore, one of anti-Nogo-A
immunotherapy’s mechanisms of action appears to be downregulation of cell surface
Nogo-A. Additionally, anti-Nogo-A antibodies that bind to Amino-Nogo could block the
binding of Nogo-A with an as of yet unidentified Amino-Nogo receptor. Finally, these
antibodies could sterically block the Nogo-A-NgR1 binding (Gonzenbach and Schwab,
2008).
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Monoclonal Antibody Binding Sites on Nogo-A

Figure 3. Monoclonal Antibody Binding Sites on Nogo-A. An illustration of the NogoA protein with amino acid locations of interest marked. The N-terminus is on the left and
the C-terminus is on the right. The monoclonal 1N-1 antibody recognizes the AminoNogo portion of Nogo-A. The monoclonal antibodies 11C7 and 7B12 recognize short
amino acid sequences within Amino-Nogo.
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NOGO-A AND NEUROLOGICAL DISORDERS
Alzheimer’s Disease
There is evidence that Nogo proteins and NgR may play a role in the
pathophysiology of Alzheimer’s disease, possibly by modulating amyloid precursor
protein (APP)/ Aβ metabolism (Park et al., 2007). Nogo-A expression is increased in the
hippocampus and frontal cortex of aged subjects with Alzheimer’s disease (Gil et al.,
2006a). In addition, Nogo-A immunoreactivity can be found in neuritic plaques (Gil et
al., 2006a), as well as NgR immunoreactivity (Park et al., 2006b). An additional report
showed increased NgR expression in hippocampal neurons in subjects with Alzheimer’s
disease (Zhu et al., 2007). Additionally, in Alzheimer’s disease Nogo-A expression is
enhanced in neuronal cell bodies, while NgR expression is decreased in cell bodies (Park
et al., 2006b).
The NgR was found to physically interact with APP. Studies with APPswe/PSEN1(∆E9) double transgenic mice demonstrate that NgR affects Aβ accumulation and
dystrophic neurite formation. When the double transgenic mice are also modified to lack
the NgR, the levels of Aβ, and Aβ plaques are increased and there are also increased
dystrophic neurites. On the other hand, if NgR(310)ecto-Fc was infused into the cerebral
ventricle of the double transgenic mice, the levels of Aβ, and Aβ plaques were decreased
and there were also fewer dystrophic neurites (Park et al., 2006b). In another approach,
NgR(310)ecto-Fc was delivered subcutaneously to the double transgenic mice, and the
levels of Aβ, and Aβ plaques were decreased and there were also fewer dystrophic
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neurites, less astrocytosis and improved performance on a spatial memory task (Park et
al., 2006a).
In addition, members of the reticulon family, including Nogo proteins which are
reticulon 4, interact with β-site APP cleaving enzyme 1 (BACE1) to inhibit the enzyme’s
activity (He et al., 2004; He et al., 2006). Reticulon proteins and BACE1 interact via an
amino acid sequence within the C-terminus of reticulon proteins in the reticulon
homology domain (He et al., 2006).

Motor Neuron Diseases
Nogo-A may be a disease marker for amyotrophic lateral sclerosis (ALS), and it
may also play a role in the pathogenesis of ALS (Teng et al., 2008). In 2002 researchers
found that ALS transgenic mice (G86R SOD1 overexpression) had higher Nogo-A
mRNA expression in the lumbar spinal cord and the gastrocnemius muscle than wild-type
mice. They went on to show that muscle biopsies from ALS patients have elevated levels
of Nogo-A, but there was no elevation of Nogo-A in muscle biopsies from patients with
primary muscle disease or polyneuropathy (Dupuis et al., 2002). Further research showed
that Nogo-A/B expression levels correlated with ALS disease severity (Jokic et al.,
2005). A prospective study of patients with lower motor neuron syndrome revealed that
Nogo-A in muscle biopsies detected by western blot could be used to identify patients
who would progress to ALS (Pradat et al., 2007). However, this finding was disputed by
another group who found elevated Nogo-A in muscle biopsies from other forms of
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myopathy and peripheral neuropathies (Wojcik et al., 2006). Therefore the usefulness of
Nogo-A as a biomarker for ALS remains controversial.
An additional study suggests that Nogo-A may be involved in the pathogenesis of
ALS. When ALS transgenic mice (G86R SOD1 overexpression) were also genetically
modified to lack Nogo-A, the mice survived longer, had attenuated loss of motor neurons
and less muscle denervation. Furthermore, overexpression of Nogo-A in wild-type mice
led to disruption of the neuromuscular junction with postsynaptic shrinkage and
presynaptic retraction (Jokic et al., 2006). However, in a somewhat contradictory report a
NgR agonist Pep4 and a NgR antagonist NEP1-40 both can attenuate motor neuron loss
after neonatal sciatic nerve lesion (Dupuis et al., 2008). Therefore, the role of Nogo-A
and the NgR in the pathogenesis of ALS remains unclear.

Psychiatric Disorders
There is evidence that decreased NgR1 signaling may increase the risk for
schizophrenia (Budel et al., 2008). The NgR1 gene is located within the 22q11 locus
which has been linked to schizophrenia risk, and polymorphisms in the NgR1 gene are
associated with schizophrenia (Liu et al., 2002; Sinibaldi et al., 2004; Hsu et al., 2007;
Budel et al., 2008). However, in the Chinese population there appears to be no
association between NgR1 gene variation and schizophrenia (Chen et al., 2004). The
variants in the NgR1 gene associated with schizophrenia are rare, but may affect the
functioning of the receptor. Four NgR1 variants were evaluated for their functional
properties, and it was shown that the variants were not able to inhibit growth cone
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collapse and acted as dominant-negatives (Budel et al., 2008). Mice genetically modified
to lack the NgR1 were tested for behaviors affected by schizophrenia. The mice lacking
NgR1 showed impairment on a working memory task in one study (Budel et al., 2008)
but not in another study (Hsu et al., 2007). Sensorimotor gating as measured by prepulse
inhibition (PPI) was unaltered in mice lacking the NgR1 (Hsu et al., 2007; Budel et al.,
2008), though a subset of these mice lacked a PPI response (Budel et al., 2008).
In 2002 Nogo was also implicated as being involved in schizophrenia when Nogo
mRNA was found to be overexpressed in the frontal cortex of schizophrenic individuals
(Novak et al., 2002). In this study no distinction was made between Nogo-A, -B and –C,
so a further study was undertaken which found that Nogo-C was overexpressed in
schizophrenia but not Nogo-A or –B. Furthermore Nogo-B was found to be
underexpressed in depression, and there were no changes in Nogo-A, -B or –C in bipolar
disorder (Novak et al., 2006). Some studies have shown an association between
polymorphisms in the gene for Nogo with schizophrenia (Novak et al., 2002; Tan et al.,
2005), while other studies have not replicated this result (Covault et al., 2004; Gregorio et
al., 2005; Xiong et al., 2005). Therefore, Nogo and NgR may be involved in several
psychiatric disorders and in particular schizophrenia, possibly by modifying the genetic
risk.

Epilepsy
Nogo-A protein levels have been shown to be increased in the hippocampus in
individuals with temporal lobe epilepsy (Bandtlow et al., 2004; Gil et al., 2006a). This
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result has also been replicated in several experimental models of epilepsy. After kainateinduced seizures in rats Nogo-A mRNA expression was increased in hippocampal
neurons (Meier et al., 2003). However, another study of kainate-induced seizures in rats
showed a transient downregulation of Nogo and NgR mRNA in the hippocampus
(Mingorance et al., 2004a), and another study showed no change in Nogo mRNA in the
hippocampus (Josephson et al., 2001). In these two studies no distinction was made
between Nogo-A, -B and –C. In a mouse genetic model of temporal lobe epilepsy
(mceph/mceph) there was an upregulation of Nogo-A and NgR mRNA in the
hippocampus (Lavebratt et al., 2006). In another study with amygdala kindling, rats
showed increased Nogo-A and Ng-R protein expression in the ipsilateral hippocampus
(Takeda et al., 2007). Therefore, Nogo-A and NgR expression may be regulated by
epilepsy but it is unclear what role this may play in the pathogenesis of the disease.

Multiple Sclerosis
Nogo-A and NgR have been investigated as disease markers for multiple
sclerosis. One study showed that a soluble Nogo-A product was present in the cerebral
spinal fluid of individuals with multiple sclerosis, but not in control subjects (Jurewicz et
al., 2007). However, another study disputed this claim and concluded that the detected
protein was a immunoglobulin light chain and not a soluble Nogo-A product (Lindsey et
al., 2008).
There is also evidence that Nogo-A and NgR may be involved in the pathogenesis
of multiple sclerosis. Autoantibodies against the N-terminus of Nogo-A (IgM) are
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detectable in the serum and are elevated in patients with multiple sclerosis as compared to
controls. In addition, autoantibodies against the N-terminus of Nogo-A (IgG) are
detectable in the cerebral spinal fluid and are higher in relapsing-remitting multiple
sclerosis than in chronic progressive multiple sclerosis (Reindl et al., 2003).
Autoantibodies against the Nogo-66 sequence and the NgR (IgG) have also been
identified in the serum of patients with multiple sclerosis, though they were also found in
controls (Onoue et al., 2007). These autoantibodies may simply be a consequence of the
disease, they may mediate further injury, or they may play a role in repair (Reindl et al.,
2003).
A further study suggested that anti-Nogo-A antibodies may be protective in
multiple sclerosis. Mice underwent vaccination with Nogo-A, or were injected with an
anti-Nogo-A IgG and then experimental autoimmune encephalomyelitis (EAE), a model
of multiple sclerosis, was induced. Mice with antibodies against Nogo-A had decreased
incidence and severity of EAE. Additionally, in genetically modified mice that lacked
Nogo-A,-B and –C, EAE was delayed, less severe, and shorter in duration (Karnezis et
al., 2004). Taken together, this suggest Nogo-A may be a therapeutic target in multiple
sclerosis.
Nogo-A and NgR1 signaling may play a role in multiple sclerosis via immune
cells. One study reported that Nogo-A was upregulated in oligodendrocytes, and NgR1
was upregulated in reactive astrocytes and microglia/macrophages in multiple sclerosis
demyelinating lesions (Satoh et al., 2005). A recent report showed that NgR1 is found in

33
human B cells, T cells and monocytes and that NgR1 can affect the motility of immune
cells in the presence of myelin (Pool et al., 2009).
Nogo-A is also involved in oligodendrocyte differentiation. In mice genetically
modified to lack Nogo-A a delay in oligodendrocyte differentiation was observed in the
optic nerve and cerebellum. Additionally, at P15 the Nogo-A knock-out mice had
hypomyelinated optic nerves with axons of decreased caliber, but myelination and axon
caliber reached normal levels by P28. In Nogo-A knock-out mice myelin structure and
the nodes of Ranvier were not disrupted (Pernet et al., 2008). The role that Nogo-A plays
in oligodendrocyte differentiation could have implications for remyelination in multiple
sclerosis.

EXPRESSION OF NOGO-A IN NEURONS
Nogo-A is often thought of as a myelin associated protein, but Nogo-A mRNA
and protein is also found in many neurons (Josephson et al., 2001; Huber et al., 2002;
Hunt et al., 2003; Meier et al., 2003; Mingorance et al., 2004a). In the human
hippocampus, Nogo-A protein is expressed by pyramidal neurons, non-pyramidal
neurons and granule cells (Buss et al., 2005; Gil et al., 2006a). In the human cerebral
cortex neurons in all layers express Nogo-A protein (Buss et al., 2005). In the rat
hippocampus, Nogo-A protein is expressed by pyramidal neurons, non-pyramidal
neurons and granule cells (Huber et al., 2002; Hunt et al., 2003). In the rat hippocampus
the expression of Nogo-A appears to be related to the location of different afferent
terminations. For example, in locations where the lateral entorhinal cortex has
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terminations like in the stratum lacunosum-moleculare of the CA1 and subiculum border
and CA3, Nogo-A expression is higher (Mingorance et al., 2004a). In the rat cerebral
cortex neurons in all layers express Nogo-A protein (Huber et al., 2002; Hunt et al.,
2003). Nogo-A expression in neurons is also found at many other locations such as the
retina, red nucleus and cerebellum (Huber et al., 2002; Hunt et al., 2003).

POTENTIAL FUNCTIONS OF NEURONAL NOGO-A
Axonal Growth
Nogo-A in oligodendrocytes as been implicated in inhibiting axonal growth for
some time (Gonzenbach and Schwab, 2008), but new evidence suggests that neuronal
Nogo-A may also inhibit axonal growth (Montani et al., 2009). Dorsal root ganglia
(DRG) neurons were isolated from mice genetically modified to lack Nogo-A and wildtype mice. DRG neurons from mice lacking Nogo-A had larger and more motile growth
cones than wild-type mice. Additionally, in DRG neurons from Nogo-A knock-out mice
there was increased phosphorylation of LIMK1 and increased activated Rho (RhoGTP).
This is significant because the RhoGTP/LIMK1/Cofilin pathway regulates actin
dynamics (Montani et al., 2009).

Synaptic Plasticity
Further evidence points to a role in the adult for neuronal Nogo-A in synaptic
plasticity. Nogo-A is located at the post-synaptic density of spinal cord motor neurons
(Liu et al., 2003), and is located presynaptically at the neuromuscular junction (Dodd et
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al., 2005). Genetic manipulation to specifically overexpress Nogo-A in Purkinje cells led
to the retraction and loss of inhibitory Purkinje cell terminals, suggesting a role for
neuronal Nogo-A in the maintenance of inhibitory synapses (Aloy et al., 2006). Nogo-A
has also been shown to inhibit integrin signaling (Hu and Strittmatter, 2008), and
integrins have been implicated in regulating dendritic spine morphology (Webb et al.,
2007). The NgR1 has also been shown to be involved in synaptic plasticity. In the cortex
the NgR1 is located both pre and post-synaptically (Wang et al., 2002c), and mutant mice
without NgR1 have a shift of dendritic spine morphologies in the apical CA1 pyramidal
cell dendritic tree so there are more stubby spines and fewer mushroom and thin spines as
compared to heterozygous controls (Lee et al., 2008). This represents a shift towards
more immature dendritic spine morphologies. In this study, mice lacking NgR1 had
enhanced FGF2-dependent long term potentiation (LTP) and attenuated long term
depression (LTD) at hippocampal Schaffer collateral-CA1 synapses. Taken together,
these studies suggest that neuronal Nogo-A and its receptor NgR1 play a role in synaptic
plasticity.

Structure of the Endoplasmic Reticulum
Nogo-A, like all of the reticulon proteins, is highly localized to the endoplasmic
reticulum (GrandPre et al., 2000; Oertle et al., 2003). Immunogold staining of Nogo-A
shows Nogo-A localized at the rough endoplasmic reticulum (Jin et al., 2003b). Although
Nogo-A is located in the peripheral endoplasmic reticulum, it is absent from the nuclear
envelope. A report showed that Nogo-A plays a role in the shaping of tubular

36
endoplasmic reticulum (Voeltz et al., 2006). The authors speculated that Nogo-A may
stabilize highly curved membranes.

Central Nervous System Development
Growing evidence points to a role for Nogo-A in CNS development. During
development the expression of Nogo-A in the brain precedes that of the NgR (Wang et
al., 2002c). Additionally, Nogo-A is more highly expressed during development than
during adulthood in many neuronal populations, with the exception of the hippocampus
(Huber et al., 2002; Meier et al., 2003). In mice genetically modified to lack Nogo-A,-B
and –C, developing cortical cells in vitro showed early polarization and increased
branching (Mingorance-Le Meur et al., 2007), suggesting Nogo-A is involved in cortical
development. Additionally, during development large projection neurons of the chick
optic tectum express Nogo-A during the process of neuritogenesis (Caltharp et al., 2007).
Another study showed that Nogo-A is expressed in developing olfactory receptor neurons
during axonal growth (Richard et al., 2005). We have previously reported that knocking
down Nogo-A during development in neocortical pyramidal neurons led to decreased
dendritic spine density and an increased percentage of immature dendritic spine
morphologies (Pradhan, 2007). Taken together, these studies of Nogo-A during
development support the idea that neuronal Nogo-A has a role in CNS development,
circuit formation, and structural synaptic plasticity.
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There is also evidence that Nogo-A and NgR signaling consolidate neural
pathways after development. Mice genetically modified to lack Nogo-A and –B
demonstrate ocular dominance plasticity after the critical period (McGee et al., 2005).
Further support for a role for Nogo-A in development of the CNS comes from
behavioral characterization of mice genetically modified to lack Nogo-A. Adult mice
lacking Nogo-A had improved motor coordination and balance, increased locomotion in
the dark phase of the light-dark cycle, and increased locomotor response to amphetamine
treatment (Willi et al., 2008b). These findings suggest that Nogo-A may play a role in the
development of the cerebellum and the dopaminergic system.

Peripheral Nerve Development and Regeneration
Evidence has emerged that Nogo-NgR signaling may be involved in peripheral
nerve axon pathfinding by acting as a negative guidance cue. Zebrafish, like mammals,
express three splice variants of Nogo known as Nogo-α, -β, and -γ, and they are
conserved only at the C-terminus where the reticulon homology domain containing
Nogo-66 is located. They are not conserved at the Nogo-A, and –B specific N terminal
domains. When protein synthesis for NgR or Nogo-γ was disrupted in zebrafish embryos,
CNS development was grossly unaffected, but peripheral nerves were shorter, thinner,
defasciculated and branched into aberrant locations (Brosamle et al., 2009). In rats during
development and adulthood, Nogo-A is expressed in peripheral ganglia such as the dorsal
root ganglion (Josephson et al., 2001; Huber et al., 2002), and peripheral nerve fibers
(Huber et al., 2002). Expression of Nogo-A in peripheral ganglia in fetal and adult human
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tissue has also been demonstrated (Josephson et al., 2001). Though Nogo-A mRNA was
restricted to neuron cell bodies, suggesting that Schwann cells and the perineurium in
peripheral nerves do not express Nogo-A (Huber et al., 2002). Additionally, after the
sciatic nerve is transected in rats, Nogo-A protein is highly expressed in the
regenerating/sprouting axons (Hunt et al., 2003). Taken together, these studies suggest
that Nogo-A and NgR is involved in the development and regeneration/sprouting of
peripheral axons.

RNA INTERFERENCE IN THE RAT BRAIN IN VIVO
RNA Interference
In 1998 Andrew Fire and his colleagues showed that injection of double-stranded
RNA into Caenorhabditis elegans could cause specific interference to endogenous
mRNA with complementary sequences (Fire et al., 1998). Then in 2001 RNAi was
demonstrated in mammalian cells in vitro (Elbashir et al., 2001). This experiment showed
that short interfering RNA (siRNA) duplexes 21-nucleotides in length could specifically
interfere with endogenous mRNA, while longer double stranded RNA cause non-specific
and specific interference. Then in 2002 specific RNAi was demonstrated in adult mice
either using siRNA or in vivo expression of a shRNA (McCaffrey et al., 2002).
RNAi using synthetic siRNA or shRNA utilizes molecular machinery for
endogenous gene silencing by microRNA (miRNA). In the RNAi endogenous pathway
primary miRNA is processed by Drosha and DGCR8 to produce precursor miRNA. This
process occurs in the nucleus, and precursor miRNA is transported to the cytoplasm by
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exportin 5. In the cytoplasm miRNA is further processed by Dicer, and then one of the
strands, known as the guide strand, is incorporated into the RNA-induced silencing
complex (RISC). The guide strand binds to a complementary sequence in mRNA, and, if
the sequences perfectly match, then the mRNA is degraded by AGO2. However, if the
sequences match imperfectly, then translational repression occurs and the mRNA may be
degraded in processing bodies in a non-sequence specific way. For this to occur there
must be at least matching in the seed region, which is at nucleotides 2-8 of the miRNA.
An additional mechanism for gene silencing, which involves transcriptional gene
silencing, can occur when siRNA is found in the nucleus. For this mechanism to occur
the siRNA must be complementary to the gene in the promoter region (for review see
Castanotto et al., 2009b).
Synthetic siRNA enters the endogenous RNAi pathway by being incorporated
into RISC. Alternatively, plasmids can be delivered to the cell that express a shRNA
under control of a polymerase II or III promoter. This shRNA then enters the endogenous
RNAi pathway by being processed by Drosh and/or Dicer (Castanotto and Rossi, 2009b).
There are several possible complications when using synthetic siRNA. The
synthetic siRNA could disrupt the endogenous RNAi. Synthetic siRNA can also cause
specific off-target interference in mRNA other than the target if the siRNA is
complementary to other mRNA (Castanotto and Rossi, 2009b). Additionally, synthetic
siRNA can also activate the immune system and production of type I interferon (Hornung
et al., 2005; Castanotto and Rossi, 2009b).
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Viral Delivery by Adeno-Associated Virus
For long-term expression of a siRNA in vivo viral delivery is used. In this
approach a vector is used to deliver a gene for a shRNA under the control of a
polymerase II or III promoter (Castanotto and Rossi, 2009b). Adeno-associated virus
(AAV) vectors are well suited for gene delivery because they can support persistent
transgene expression for chronic experiments, and the host immune response to AAV is
minimal (Daya et al., 2008).
AAV viruses belong to the Parvoviridae family and Dependovirus genus. They
are small non-enveloped viruses with a single strand of DNA. AAV requires a helper
virus, either adenovirus or herpesvirus, for productive infection. AAVs are unique in that
they can integrate into the chromosome at a specific location 19q13.4. The genome
contains two open reading frames flanked by two inverted terminal repeats. The open
reading frames contain the Rep and Cap genes (Daya and Berns, 2008).
For AAV use as a gene transfer vector the viral genes are removed and in addition
an integration efficiency element (IEE) is removed. This makes AAV vectors unable to
replicate or integrate in a site specific manner. The inverted terminal repeats are retained
because they are required for packaging of the vector. A common approach to modify
tissue transduction specificity is to package the inverted terminal repeats of one AAV
serotype into the capsids of different serotypes. There have been 12 human serotypes
identified and greater than 100 serotypes from non-human primates identified (Daya and
Berns, 2008).
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STROKE
Introduction
Ischemic stroke occurs when a blood vessel in the brain is occluded. Ischemic
stroke is most often caused by atherosclerotic disease, hypertension and emboli, though
there are many other conditions that can cause ischemic strokes. These fall into
classifications of vasculitis, connective tissue disorders, angiopathies, metabolic
disorders, hematologic and oncologic, pregnancy related, substance abuse, infections, and
migrainous infarctions (Tarulli, 2007).
Occlusion of a cerebral artery with resultant lack of blood flow causes damage to
the brain, and this damage leads to neurological impairments such as hemiparesis,
cognitive deficits, aphasia, and sensory deficits (Kelly-Hayes et al., 2003). To some
extent spontaneous recovery from neurological impairments usually occurs after stroke.
For the motor system most improvements occur during the first 3 months after a stroke.
For cognitive impairments significant improvements can occur past 3 months after a
stroke (Cramer, 2008). After this more rapid recovery, slower spontaneous recovery can
occur for years after a stroke (Hankey et al., 2007). Patients who are less severely
disabled recover more rapidly (Hankey et al., 2007).

Incidence and Prevalence
There are 6,500,000 people in the United States who have experienced a stroke,
and every year 795,000 people have a new or recurrent stroke. Stroke is the third leading
cause of death in the United States, and in addition stroke is the #1 cause of serious long-
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term disability. 87% of strokes are ischemic, 10% are hemorrhagic and 3% are
subarachnoid hemorrhage. Stroke is more prevalent in the aged population and increasing
age is a significant risk factor for stroke. In the age group of 20-39 the prevalence of
stroke in men is 0.2% of the population, while for women it is 0.3%. In the age group of
80+ the prevalence of stroke in men is 17.1% of the population while for women it is
13.5% (Lloyd-Jones et al., 2009).

Stroke in the Aged
Stroke is a disease of the aged, and 60% of people who have had a stroke are over
the age of 65 (Pleis et al., 2007). In a study of disability 6 months following an ischemic
stroke in subjects 65-94 years old, older age was associated with greater disability (KellyHayes et al., 2003). In ischemic stroke survivors over the age of 65, nearly 50% have
cognitive deficits 6 months post-stroke (Kelly-Hayes et al., 2003). Furthermore, stroke
patients without dementia at a baseline evaluation had a faster decline in memory
performance as compared to aged individuals without stroke (Reitz et al., 2006).
Therefore, age is a risk factor for stroke, and increasing age is associated with greater
disability following ischemic stroke.
Experiments in rodent models have demonstrated that the response of an aged
subject to stroke is different than the response of a younger subject (Popa-Wagner et al.,
2007b). Aged rodents functionally recover from a cortical stroke more slowly and to a
lesser extent than younger rodents (Badan et al., 2003a; Brown et al., 2003; Markus et al.,
2005b; Rosen et al., 2005; Zhang et al., 2005; Popa-Wagner et al., 2007c). The extent of
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recovery from stroke depends upon an interplay of factors causing tissue damage, factors
inhibiting repair, and factors promoting repair, and in the aged brain these factors appear
to be dysregulated in magnitude and timing (Popa-Wagner et al., 2007b). For example, in
aged rats the ischemic infarct develops more quickly and amount of apoptotic cells in the
infarct core is higher at earlier time points as compared to younger rats (Popa-Wagner et
al., 2007c). Additionally, the glial scar forms earlier in aged animals as compared to
young animals (Badan et al., 2003a). In aged rats most growth-promoting genes increase
after stroke, but this increase is delayed as compared to younger animals (Li et al., 2006).

Current Approved Therapies for Stroke
Recombinant tissue-type plasminogen activator (tPA) is the only approved
therapy for acute ischemic stroke and is effective up to 4.5 hours after the onset of
symptoms (Hacke et al., 2008). After this short time window, the therapies for stroke are
limited. Rehabilitation is often utilized and may include physical therapy, speech
pathology, occupational therapy, and neuropsychological and cognitive rehabilitation
(Adams et al., 2006). The effectiveness of cognitive rehabilitation to improve memory
impairments after stroke is unclear because there have been few randomized controlled
trials (das Nair et al., 2007). Therefore, there is a great need for therapies to improve
stroke outcome.
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SPATIAL MEMORY
Brain Structures Involved and Connectivity
In 1981 Richard Morris described the Morris water maze as a test of spatial
memory (Morris, 1981). In this report the hidden platform test was described as a test for
the ability to use distal cues to locate a particular location, specifically the location of a
submerged escape platform in a pool of water. Subsequently, it has been shown that
performance on the Morris water maze is sensitive to disruption in many different brain
regions (D'Hooge et al., 2001b). This disruption could be in the form of a lesion, but
disconnecting the brain region, pharmacological manipulation or electrophysiological
manipulation can also cause deficits in performance on the Morris water maze. The
hippocampus, and more specifically the dorsal hippocampus, is a key brain structure in
performance on the Morris water maze, and afferents and efferents of principal cells in
the trisynaptic pathway are described in Fig 4. Other brain regions where disruption leads
to Morris water maze impairments include but are not limited to the striatum, basal
forebrain, cerebellum, entorhinal cortex, perirhinal cortex, prefrontal cortex, anterior
cingulated cortex, and insular cortex (D'Hooge and De Deyn, 2001b). Therefore, it
appears that a network of brain areas contribute to performance on the Morris water
maze.
One way that the brain may represent spatial information is through the firing of
“place cells,” which fire when the organism is in a specific location in space. Cells that
fire in response to place were first identified in the hippocampus, but they have also been
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found in the medial entorhinal cortex, subiculum, striatum, presubiculum, parasubiculum
and lateral septum (Knierim, 2006).
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Hippocampus Afferents and Efferents (Principal Cells)
A

Figure 4. Hippocampus Afferents and Efferents. (A) Unilateral diagram of the rat
hippocampus in a coronal section. (B) CA1 pyramidal cell, (C) CA3 pyramidal cell and
(D) Dentate Gyrus granule cell afferents (red) and efferents (green arrows and green
type) (Spruston et al., 2006). s.p.=stratum pyramidale, s.o.=stratum oriens, s.r.=stratum
radiatum, s.l.m.=stratum lacunosum-moleculare, s.l.=stratum lucidum, s.m.=stratum
moleculare, s.g.=stratum granulosum
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Hippocampus Afferents and Efferents (CA1 Pyramidal Cell)
B
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Hippocampus Afferents and Efferents (CA3 Pyramidal Cell)

C
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Hippocampus Afferents and Efferents (Dentate Gyrus Granule Cell)

D
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Cognitive Processes Involved in Performance on the Morris Water Maze
Performance on the Morris water maze involves several different cognitive
processes. The most obvious is the learning of the location of the hidden platform in
relation to distal cues. Additionally, at the start of testing rats must acquire the procedural
aspects of the task. For example, rats must learn that there is no escape in the periphery of
the pool or via the wall of the pool, and that there is an escape platform located in the
central part of the pool. Additionally, at the start of testing when the environment is
novel, rats use a process called “dead reckoning” to spatially navigate. With dead
reckoning rats keep track of their location in relation to the start location by using selfmovement cues (Whishaw, 1998; Wallace et al., 2008). Manipulations that impair Morris
water maze performance could be related to deficits in any of these cognitive processes.

DENDRITIC SPINES
Structure of Dendritic Spines as it Relates to Function
Dendritic spines are small protrusions from dendrites that are the postsynaptic
sites of most excitatory synapses in the brain. Dendritic spines can be categorized by their
shape (Fig 5). Mushroom, thin and 2-headed spines have distinct heads, while stubby
spines by definition have a head diameter that is approximately equal to the width of the
neck. Filopodia are dendritic protrusions that are abundant during development. Filopodia
may have no synapses or multiple synapses, and that can develop into either dendritic
spines or retract to form synapses on the dendritic shaft. Filopodia are also present in the
adult, but are much more scarce (Bourne et al., 2008).
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Dendritic spine morphology is of interest because the shape of a spine indicates
the strength of the synapse. Therefore, observing changes in the morphology and number
of dendritic spines is a way to observe changes in the organization and strength of
excitatory synaptic connections (Tada et al., 2006). Mushroom spines have large heads
and narrow necks, and are thought to be stronger and more stable. Mushroom spines have
larger post-synaptic densities, more AMPA receptors, are more likely to contain smooth
endoplasmic reticulum and polyribosomes, and are more likely to be associated with
astroglial processes (Bourne and Harris, 2008). Thin spines on the other hand are thought
to be more plastic because they can form and change size readily and are less stable.
Mushroom spines can last for months, while thin spines can turnover in several days. One
way to conceptualize this idea is to think of mushroom spines as “memory spines” and
thin spines as “learning spines” (Bourne et al., 2007).
The morphology of dendritic spines depends upon the actin cytoskeleton (Bourne
and Harris, 2008). Interestingly, several of the molecules downstream of Nogo-A
signaling act on the actin cytoskeleton and affect the morphology of dendritc spines. It
has been demonstrated that RhoA and ROCK shortens spines (Tashiro et al., 2008),
LIMK1 promotes enlargement of spines (Meng et al., 2002; Schratt et al., 2006), and
cofilin promotes shrinkage of spines (Chen et al., 2007).
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Common Dendritic Spine Morphologies

Figure 5. Common Dendritic Spine Morphologies. These classifications are made
based upon the relationship between the head diameter and neck width. For example,
mushroom spines have head diameters that are much larger than the neck width. On the
other hand in stubby spines the head diameter is the same as the neck width. Filopodial
protrusions are not considered to be dendritic spines, but instead may act as precursors to
dendritic spines.

CHAPTER THREE
IMPROVED PERFORMANCE ON THE MORRIS WATER MAZE AFTER
STROKE AND ANTI-NOGO-A IMMUNOTHERAPY IN AGED RATS
ABSTRACT
We have previously shown that immunotherapy directed against the protein
Nogo-A leads to recovery on a skilled forelimb reaching task in rats after sensorimotor
cortex stroke and this improvement correlated with axonal and dendritic plasticity. Here
we investigated anti-Nogo-A immunotherapy as an intervention to improve performance
on a spatial memory task in aged rats after stroke, and whether cognitive recovery was
correlated with structural plasticity. Aged rats underwent a unilateral permanent MCAO
and one week later were treated with an anti-Nogo-A or control antibody. Nine weeks
post-stroke, treated rats and normal aged rats were tested on the Morris water maze task.
Following testing rats were sacrificed and brains processed for the Golgi-Cox method.
Hippocampal CA3 and CA1 pyramidal and dentate gyrus granule cells were examined
for dendritic length and number of branch segments, and CA3 and CA1 pyramidal cells
were examined for spine density and morphology. Anti-Nogo-A immunotherapy given
one week following stroke in aged rats improved performance on the reference memory
portion of the Morris water maze task. However, this improved performance was not
correlated with structural changes in hippocampal CA3 and CA1 pyramidal or dentate
gyrus granule cells. Our finding of improved performance on the Morris water maze in
aged rats after stroke and treatment with anti-Nogo-A immunotherapy demonstrates the
53
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promising therapeutic potential for anti-Nogo-A immunotherapy to treat cognitive
deficits after stroke.
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INTRODUCTION
Each year 795,000 people in the United States have a new or recurrent stroke, and
87% of these events are caused by blockage of a cerebral artery (Lloyd-Jones et al.,
2009), leading to ischemic brain damage. Such brain damage often results in long-term
neurological deficits in various functions including cognition. The risk of stroke increases
with age (Lloyd-Jones et al., 2009) and in the elderly population more advanced age is
associated with greater disability after ischemic stroke (Kelly-Hayes et al., 2003). This is
thought to be due at least in part to the differential response of the aged brain to ischemia,
including increased neuronal degeneration and apoptosis (Popa-Wagner et al., 2007c),
faster onset of inflammation and scar formation (Badan et al., 2003b), and increased
DNA damage and oxidative stress (Li et al., 2005a; Popa-Wagner et al., 2007a).
Therefore, in order to best investigate the therapeutic potential of emerging therapies for
stroke recovery, using the appropriate age group in animal models of stroke is important
and recommended by the Stroke Therapy Academic Industry Roundtable (STAIR, 1999)
and the Stroke Progress Review Group (Grotta et al., 2008).
Spontaneous recovery of function after stroke is thought to be limited by the
growth inhibitory environment in the adult CNS, which includes the myelin-associated
inhibitors (Gonzenbach and Schwab, 2008). The potent myelin inhibitor Nogo-A was
first identified as a neurite growth inhibitory protein in vitro (Caroni et al., 1988b; Caroni
and Schwab, 1988a; Chen et al., 2000a; GrandPre et al., 2000; Prinjha et al., 2000) and
then as an inhibitor of axonal regeneration and compensatory growth and recovery of
function in models of spinal cord injury (Gonzenbach and Schwab, 2008). Subsequently
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we have shown that anti-Nogo-A immunotherapy after focal ischemic stroke leads to
functional recovery in a skilled sensorimotor test in adult and aged rats (Papadopoulos et
al., 2002a; Markus et al., 2005a; Seymour et al., 2005a; Tsai et al., 2007). The functional
recovery in adult rats was correlated with axonal compensatory growth (Papadopoulos et
al., 2002a; Markus et al., 2005a; Seymour et al., 2005a), and increased dendritic
arborization and spine density in the contralesional sensorimotor cortex (Papadopoulos et
al., 2006), indicating that recovery of sensorimotor function after cortical injury may be
achieved by dis-inhibiting sprouting in axons and dendrites by strategies to neutralize the
Nogo-A protein.
Importantly, ischemic stroke can lead to other types of neurologic deficits other
than sensorimotor impairment, including cognitive disorders. Therefore, we investigated
the therapeutic potential of anti-Nogo-A immunotherapy on cognitive recovery after
ischemic stroke in aged animals. We found that anti-Nogo-A immunotherapy given one
week after stroke in aged rats improved performance on a spatial memory task, but was
not correlated with increased dendritic complexity or increased spine density in
hippocampal neurons.

METHODS
Animal Subjects
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Aged male Long Evans black-hooded rats (18 months
of age at start of the study) were divided into three groups: (1) Normal aged (n=10), (2)

57
MCAO/control antibody treatment (n=13), and (3) MCAO/anti-Nogo-A antibody
treatment (n=12). Rats were double housed, except in the case of three rats in which one
rat’s cage-mate died after surgery, and two rats were cage-mates and had to be separated
due to fighting. Rats were maintained in a 12 hour light/dark cycle, with free access to
food and water. Behavioral testing was performed during the light phase. Rats in both
stroke groups and the normal aged rats were weighed and evaluated on a 3 point score for
activity level (1=sick, 2=low activity, 3=normal activity) and for coat condition (1=dirty
and rough, 2=moderate, 3= smooth and shiny) at least once per week.

Stroke Surgery
MCAO was performed as in Chen et al. (Chen et al., 1986), and as in our previous work
(Papadopoulos et al., 2002a; Markus et al., 2005a; Seymour et al., 2005a; Papadopoulos
et al., 2006; Tsai et al., 2007). Briefly, rats were anesthetized with isoflurane inhalant
anesthesia (3% in oxygen). Through an anterior cervical incision the bilateral common
carotid arteries (CCA) were isolated. Rats were placed in a stereotaxic frame and a 2 cm
vertical incision was made between the right eye and right ear and the temporalis muscle
retracted. A burr hole exposed the MCA and the artery was ligated with a 10-0 suture and
transected above the suture with microscissors. The right CCA was permanently ligated
with 5-0 chromic gut suture, and the left CCA was occluded for 60 minutes with an
aneurysm clip. The surgical wound was closed and the rats were returned to pervious
housing for one week until antibody infusion as below.
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Antibody Intracerebroventricular Infusion
The experimental design is depicted in Fig 6. One week post-stroke, rats were
randomized and anesthetized with isoflurane inhalant anesthesia (3% in oxygen). Rats
were placed in a stereotaxic frame and a midline incision was made in the scalp. A burr
hole on the same side as the stroke lesion exposed the cortex. A cannula was placed into
the right lateral cerebral ventricle at coordinates 1.3 mm lateral, 0.8 mm posterior, and
3.8 mm ventral (relative to bregma) and secured to the skull with cyanoacrylate gel.
Through a mid-scapular incision an Alzet osmotic minipump (model 2ML2; Durect
Corporation, Cupertino, CA, USA) was implanted subcutaneously posterior to the
scapulae and connected to the cannula with polyethylene tubing. Either purified mouse
monoclonal anti-Nogo-A antibody (11C7, IgG1) or control antibody (anti-wheat auxin,
IgG1) was infused at a rate of 15 µg/hr (2.5 mg/ml) for two weeks, after which the
animals are again anesthetized and the pumps removed.

Morris Water Maze
Morris water maze testing started 9 weeks post-stroke. Experimenters were blinded to
antibody treatment. Rats were handled for five consecutive days, excluding weekends,
prior to stroke surgery and then once weekly until one week before Morris water maze
testing when they were again handled for five consecutive days. The apparatus consisted
of a galvanized steel circular tank with a diameter of 6 feet and a depth of 2 feet filled
halfway with water (20-22º) colored white with tempura paint. A 4 inch by 4 inch topped
plexiglass platform covered in a white sock for traction was located just below the
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surface of the water. Prominent distal cues in the room including posters, cabinets, and
blacked out windows remained constant throughout testing.

PLACE TASK. During days 1-7 of testing the hidden platform was always located in the
same position in the NE quadrant of the pool. Rats were given four trials per day starting
from each of the four cardinal locations (N, E, S and W) in a random order. Trials were
separated by at least five minutes. When rats reached the platform, they were allowed to
remain there for 30 seconds, and then removed. If rats did not find the platform in 2
minutes then the experimenter guided the rat to the platform with her hand. In between
trials rats were dried with a towel and returned to their home cages. The place task
evaluates the rats’ ability to learn about the environmental cues to guide movement
toward the hidden platform.

PROBE TRIAL. On day 8 of testing the platform was removed from the pool and the rats
were given one probe trial lasting 2 minutes and starting from the west start location. The
probe trial tests whether the rats prefer the pool quadrant where the platform was
previously located during the place task.

MATCHING-TO-PLACE TASK. On days 9-13 of testing the platform location was
moved each day in the sequence as follows: SE, NW, SW, NE, and SW quadrants. Rats
were given two trials per day from the W start location, and trials were separated by 20
seconds. Rats remained on the platform for 30 seconds. If rats did not find the platform in
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4 minutes then the experimenter guided the rat to the platform with her hand. In between
trials rats were placed in a bucket on the floor of the testing room. The matching-to-place
task evaluates the rats’ ability to update their representations of the hidden platform.

Behavioral Analysis
All water maze trials were recorded to DVD using an overhead bullet camera. Ethovision
3.1 (Noldus Information Technology, Leesbug, VA, USA) video tracking software was
used to digitize the trials.

PLACE TASK. Both time and distance to locate the platform from each of the four trials
per day were averaged for statistical analysis.

PROBE PREFERENCE SCORE. For the probe trials the probe preference score was
calculated as [(T-A)+(T-B)+(T-C)]/3, where T is the swim time in the quadrant that
contained the platform during the place task and A, B, and C are the swim times in the
other three quadrants (Brown et al., 2000).

THIGMOTAXIS. Time spent and distance swam in the outer 50% of the pool were
generated from Ethovision 3.1 software for each rat on each of the four trials on seven
days of hidden platform testing. Thigmotaxis for time was represented as time spent in
the outer 50 % of the pool over total swim time. Thigmotaxis for distance was
represented as distance swam in the outer 50 % of the pool over total distance swam.
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PATH CIRCUITY. Path circuity was calculated as the direct distance to the platform
over the total distance traveled to the platform.

HEADING DIRECTION. Heading direction angle represents the actual trajectory of the
rat in relation to a direct trajectory toward the hidden platform (Wallace et al., 2002). A
heading direction angle of 0º indicates that the rat’s trajectory is in a direct path toward
the hidden platform. Heading direction angles at 1.2-1.5 seconds after the start of the trial
were obtained from Ethovision 3.1 software for each rat on each of the four trials per day
during the place task.

Golgi-Cox Staining
Thirteen weeks post-stroke and two weeks after completion of Morris water maze testing,
rats were overdosed with pentobarbital (100 mg/kg, i.p.) and transcardially perfused with
0.9% saline and 10,000 U heparin/liter. The brains were removed and immersed whole in
Golgi-Cox solution (Glaser et al., 1981) for two weeks. The brains were coronally
sectioned at 200 µm on a vibratome, mounted on 2% gelatinized slide and reacted as
described by Gibb and Kolb (Gibb et al., 1998). Slides were coded to blind the
experimenters to the antibody treatment group.

Stroke Size and Hippocampal Area Analysis
Golgi-Cox stained coronal brain sections were traced, and bilaterally the hippocampus
was traced, using Neurolucida software (mbf Bioscience, Williston, VT, USA) and with
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the aid of an atlas (Paxinos, 2005). Stroke size was represented as percent of the intact
contralateral hemispheric area (total area of the intact contralateral hemisphere minus
total area of the intact ipsilesional hemisphere over total area of the intact contralateral
hemisphere). Hippocampal areas were represented as a ratio of the right hippocampal
area/ left hippocampal area.

Neuroanatomical Analysis
Golgi-Cox stained hippocampal CA3 and CA1 pyramidal cells and dentate gyrus granule
cells were analyzed in the dorsal hippocampus as described below.
For illustration purposes, images of representative CA3 and CA1 pyramidal cells
and dentate gyrus granule cells were taken. Image stacks were acquired every 5 µm for
130 µm using Neurolucida software, and then a minimum intensity z projection was
generated using ImageJ software.

DENDRITIC BRANCHING AND LENGTH. An average of four apical and basilar
dendritic trees of CA3 and CA1 pyramidal cells, and dendritic trees of dentate gyrus
granule cells were traced for each side of the hippocampus using Neurolucida software
and Leica DM 4000 B with a 63x objective. For inclusion neurons had to be well
impregnated, unobstructed by other neurons or glial cells, and intact. Dendritic trees were
analyzed for dendritic length and number of branch segments using the branched
structure analysis tool of Neurolucida. For CA3 and CA1 pyramidal cells, branches
originating from the cell body (basilar) or the apical shaft were considered first order, and
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the next bifurcating branches were considered second order and so on. For dentate gyrus
granule cells, branches originating from the cell body were considered first order, and the
next bifurcating branches were considered second order and so on. For CA3 analysis 9
brains from each group were analyzed, and for CA1 and dentate gyrus analysis all brains
from each group were analyzed.

SPINE DENSITY AND MORPHOLOGY. Four CA3 and CA1 pyramidal cell apical
dendritic terminal branches of second or higher order were analyzed for each side of the
hippocampus using a 100x oil immersion lens. For a 50 µm length segment of the branch
dendritic protrusions were counted and assigned to a morphology category of filopodium,
2-headed, stubby, thin, and mushroom shaped as described by Bourne and Harris (Bourne
and Harris, 2008). The first 10 µm of the dendrite after the branch point and the terminal
10 µm were excluded from analysis. For CA3 analysis 9 brains from each group were
analyzed, and for CA1 analysis 9 brains from the normal aged group were analyzed, 9
from the stroke/control antibody group, and 8 from the stroke/anti-Nogo-A antibody
group.

Statistical Analysis
P values of less than 0.05 were considered significant.

BEHAVIORAL DATA. Behavioral data analysis was performed with SAS software
(SAS Institute, Cary, NC, USA) except where noted.
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For comparison of place task time and distance to the platform we started with a
general linear model repeated measures ANOVA (SPSS, Chicago, IL, USA). The results
from this analysis are presented in Fig 10. When we examined plots of time and distance
to the platform over the seven days of the place task for each of the rats, we saw a trend
for normal aged rats and stroke/anti-Nogo-A rats to have steeper slopes than
stroke/control antibody rats. To determine if there were statistically significant
differences in the slopes we used a non-linear mixed model in which a y intercept and
slope parameter were determined for each individual rat. Specifically for this analysis we
used a likelihood based χ2 test of random-effects simple exponential two-parameter
model, η ( x) = θ1e −θ 2 x , where x = day – 1 (Haines et al., 2004; Clementz et al., 2008). We
did not need to correct for velocity because swim velocities during the place task did not
differ between groups (p=0.2476; Fig 12). This model was able to identify more subtle
differences in performance on the Morris water maze in aged rats, which have greater
variability in Morris water maze testing.
For comparison of swim velocities we used a repeated measure ANOVA. For
comparison of probe preference scores we used a one-way ANOVA SigmaStat (Systat,
San Jose, CA, USA). For comparison of the matching-to-place task times to swim to the
platform we used a two-way repeated measures ANOVA. For comparison of thigmotaxis
we used a likelihood based χ2 test of random-effects simple exponential three-parameter
model, η ( x) = θ1e −θ2 x + θ 3 , where x = day – 1. For comparison of the path circuity,
weight, activity score and coat score we used a repeated measures ANOVA followed by a
Bonferroni post-hoc test using the SPSS software.
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For comparison of heading direction angles we first generated angular variance,
also known as the length of the mean vector (r), for each rat for each of the seven days of
the place task using the Oriana circular statistics program (RockWare Inc., Golden, CO,
USA). Angular variance ranges from 0 to 1, with 0 meaning that the rat’s heading
direction angles are random, and with a 1 meaning that the rat’s heading direction angles
are all in the same direction. We then compared angular variances across groups using a
repeated measures ANOVA (SPSS). Secondly, we generated a mean heading direction
angle, ranging from 0-360º, for each rat for each of the seven days of the place task using
Oriana. We then compared mean heading direction angles across groups for each day of
the place task using the Watson-Williams F test with Oriana (Wallace et al., 2002).

NEUROANATOMICAL DATA. Neuroanatomical data analysis was performed with
SigmaStat as follows: a t-test for stroke size, a one-way ANOVA with Student-NewmanKeuls post-hoc for comparison of hippocampal areas, and dendritic arbor branching and
length (in cases when the data was not normal and we used a Kruskal Wallis one-way
ANOVA on ranks with Dunn’s method post-hoc), and a one-way ANOVA for
comparison of spine density and morphology.
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Experimental Timeline

Figure 6. Experimental timeline. Aged rats underwent MCAO and one week later
infusion of a anti-Nogo-A antibody or control antibody began. Nine weeks post-stroke,
treated rats and normal aged rats began training on the Morris water maze to assess
spatial memory. After completion of behavioral testing, rats were sacrificed and the
brains processed for the Golgi-Cox stain. MTP=Matching-to-Place task
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RESULTS
Health of aged rats post-stroke
After MCAO both stroke groups lost about 100 grams of weight as compared to
unlesioned normal aged rats, and there was no difference between the weight lost by the
two stroke groups (normal aged vs. stroke/control antibody p=0.002, normal aged vs.
stroke/anti-Nogo-A antibody p=0.003, stroke control antibody vs. stroke/anti-Nogo-A
antibody p=1.00; Fig 7A). To determine if general activity level, or grooming behavior is
affected by stroke in aged rats we assessed rats each week for activity level and condition
of the coat. We detected no differences between groups for activity level (p=0.051; Fig
7B) and coat condition (p=0.390; Fig 7C).
Some aging related health problems were observed and included 5 rats with
subcutaneous tumors, 2 rats with cysts, and 1 rat with a small pituitary tumor. However,
it was not necessary to drop any of these animals from behavioral testing or
neuroanatomical analysis.

Stroke size did not differ between the two stroke groups
Analysis of the stroke lesions showed a mean size of approximately 22% of the intact
contralateral hemisphere and included the sensorimotor cortex with minimal subcortical
involvement (Fig 8). The size of the stroke lesion did not significantly differ between the
stroke/control antibody group and the stroke/anti-Nogo-A antibody group (p=0.706; Fig
8B).
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Ratio of right hippocampal areas to left hippocampal areas showed slight
differences
Analysis of hippocampal areas was performed by taking a ratio of the right hippocampal
areas to the left hippocampal areas. The right hippocampus is ipsilateral to the
sensorimotor cortex stroke. A value of 1 means that the right and left hippocampus have
equal areas. There was a significant effect for group (p=0.024), and post-hoc analysis
showed a significant difference between the normal aged group and the stroke/control
antibody group (p=0.020). The stroke/control antibody group mean was 1.149, while the
normal aged group mean was 1.038, demonstrating that the stroke/control antibody group
had slightly larger right hippocampus to left hippocampus ratios than the normal aged
group. The normal aged group was no different from the stroke/anti-Nogo-A antibody
group (p=0.233), and the stroke/control antibody group was no different from the
stroke/anti-Nogo-A antibody group (p=0.097). The slight difference between the normal
aged and stroke/control antibody groups may be due to the limitations of tracing
structures on Golgi-Cox processed tissue and is probably not a meaningful difference.

Performance on the spatial reference memory task is improved in aged rats after
stroke and treatment with anti-Nogo-A immunotherapy
Rats were tested over seven days in the place task, a spatial reference memory task. At
the start of the place task animals in all groups found the hidden platform in a similar
time frame (p= 0.2122; Fig 11A, A’). As testing continued the rate at which rats in the
stroke/anti-Nogo-A antibody group acquired the hidden platform location was faster than
the stroke/control antibody group (p=0.00001). In fact, the stroke/anti-Nogo-A antibody
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group was indistinguishable from the normal aged group (p=0.1573), while the rate at
which the stroke/control antibody group acquired the hidden platform location was
slower than the normal aged group (p=0.00001). These findings were supported by
analyzing the distance the rats took to locate the hidden platform. At the start of the place
task animals in all groups swam similar distances to locate the platform (p= 0.2122; Fig
11B, B’). As testing continued the rate at which rats in the stroke/anti-Nogo-A antibody
group acquired the hidden platform location was faster than the stroke/control antibody
group (p=0.0003). However, both stroke groups had slower rates to acquire the hidden
platform location than the normal aged group (p=0.0055 for stroke/anti-Nogo-A
antibody, p ≈ 0 for stroke/control antibody). Taken together, these results indicate that
rats in the stroke/anti-Nogo-A antibody group acquired the hidden platform location
faster than rats in the stroke/control antibody group.
At the completion of the place task, a probe trial was undertaken to assess if
animals knew the former hidden platform location. All groups equally preferred the
quadrant where the platform was previously located with no significant differences
between groups (p=0.876; Fig 13). Therefore, at the end of the place task all groups had
equally learned the hidden platform location.

Performance on a spatial working memory task is unaltered by stroke and antibody
treatments
Following the probe trial, rats were tested on the matching-to-place task, a spatial
working memory task. Rats in all groups found the platform faster on trial 2 than on trial
1 (p<0.0001), and there were no significant differences between groups (p=0.4387 for

70
trial 1, p=0.0550 for trial 2; Fig 14). Therefore, all groups performed equally well on the
matching-to-place task, and there was no apparent effects of stroke on spatial working
memory.

Effects of stroke on behavior observed during the place task
Thigmotaxis was defined as swimming in the outer 50% of the pool area. At the start of
the place task all groups swam similar times in the periphery of the pool (p=0.1572; Fig
15A, A’). As testing continued both stroke groups significantly spent more time
swimming in the periphery of the pool as compared to normal aged rats (p=0.0006), and
the two stroke groups were not significantly different from each other (p=0.4028). At the
end of the place task all groups swam similar times in the periphery of the pool
(p=0.5220). Thigmotaxis for distance showed similar results with the two stroke groups
swimming significantly more distance in the periphery of the pool as compared to normal
aged (p=0.0003; Fig 15B, B’). Therefore, rats with stroke regardless of treatment spent
more time than normal aged rats in the periphery of the pool.
Path circuity is defined as the ratio of the direct distance to the platform/ the
actual swim distance to the platform during a trial. Both stroke groups swam significantly
less direct paths to the platform than normal aged rats (p=0.015 for stroke/control
antibody, p=0.023 for stroke/anti-Nogo-A antibody; Fig 16), and the two stroke groups
were not significantly different from each other (p=1.00). Therefore, rats with stroke
regardless of treatment took less direct paths to reach the platform, as compared to
normal aged rats.
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Swim paths taken during Morris water maze testing
Swim paths from one animal in each group for the place task, probe trial and matchingto-place task are shown in Figures 17-22.
To analyze what swim trajectory the rats took at the start of each trial we analyzed
heading angles in relation to the platform for all place task trials at 1.2 to 1.5 seconds
after the start of the trial for angular variance and mean angle. These are used as a
measure of how accurate the swim path direction was for the platform at the beginning of
each trial during the place task. Angular variance, or the spread of the heading direction
angles for each rat, across the seven days of the place task did not significantly differ
between groups (p=0.345; Fig 23). On day two of the place task the mean heading
direction angle for the stroke/control antibody treated group significantly differed from
the stroke/anti-Nogo-A treated group (p=0.014; Fig 24). Mean angles did not
significantly differ between groups on the other six days of the place task (Fig 24).

Dendritic complexity was slightly reduced in the hippocampus on the same side as
the stroke in both stroke groups
Following behavioral testing and 13 weeks post-stroke, we examined the dendritic arbors
of Golgi-Cox stained hippocampal CA3 and CA1 pyramidal cells and dentate gyrus
granule cells (Fig 25).
For CA3 pyramidal cells, first we compared the total number of branch segments
and total dendritic length for the apical and basilar dendritic trees across groups. In CA3
pyramidal cell apical dendritic trees ipsilateral to the stroke both stroke groups had
significant decreases as compared to normal aged rats in total number of branch segments
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(p<0.001), and total dendritic length (p<0.05; Fig 26A). In CA3 pyramidal cell basilar
dendritic trees ipsilateral to the stroke both stroke groups had significant decreases as
compared to normal aged rats in total number of branch segments (p<0.05), but there
were no significant differences in total dendritic length (p=0.100; Fig 26B). Next we
compared the number of branch segments and dendritic length of CA3 pyramidal cells by
branch order across groups. In CA3 pyramidal cell apical dendritic trees ipsilateral to the
stroke both stroke groups had significant decreases as compared to normal aged rats in
number of branch segments (1st , 2nd, 4th, 5th orders, and 3rd order only for stroke/control
antibody), and dendritic length (0 order i.e. apical dendrite, and 1st order; Fig 26A’). In
CA3 pyramidal cell basilar dendritic trees ipsilateral to the stroke both stroke groups had
significant decreases as compared to normal aged rats in number of branch segments (3rd,
4th orders, and 1st order only for stroke/control antibody), and dendritic length (4th order;
Fig 26B’).
For CA1 pyramidal cells, first we compared the total number of branch segments
and total dendritic length for the apical and basilar dendritic trees across groups and there
were no significant differences (Fig 27A, B). Next we compared the number of branch
segments and dendritic length of CA1 pyramidal cells by branch order across groups. In
CA1 pyramidal cell apical dendritic trees ipsilateral to the stroke the stroke/control
antibody rats had significant decreases as compared to normal aged rats in number of
branch segments (1st order; Fig 27A’). In CA1 pyramidal cell basilar dendritic trees
ipsilateral to the stroke the stroke/anti-Nogo-A antibody rats had significant decreases as
compared to normal aged rats in dendritic length (2nd order; Fig 27B’).
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For dentate gyrus granule cells, first we compared the total number of branch
segments and total dendritic length for the dendritic trees across groups and there were no
significant differences (Fig 28A). Next we compared the number of branch segments and
dendritic length of dentate gyrus granule cells by branch order across groups. In dentate
gyrus granule cell dendritic trees ipsilateral to the stroke the stroke/control antibody rats
had significant decreases as compared to normal aged rats in number of branch segments
(1st order; Fig 28A’).
Therefore, there was a decrease in dendritic complexity on the same side as the
stroke in CA3, CA1 and dentate gyrus neurons in both stroke groups.

Hippocampal dendritic spine density and morphology showed no differences
between groups
Dendritic spine density of CA3 and CA1 pyramidal cell apical dendrites of second order
or higher did not significantly differ between groups (Fig 29A, C). When we analyzed
number of dendritic spines by morphology there were no significant differences between
groups for thin, stubby and mushroom spines (Fig 29B, D). Furthermore, there was no
significant difference between groups for number of filopodia (Fig 29B, D).
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Health of Aged Rats Post-Stroke
A

B

C

Figure 7. Health of aged rats post-stroke. Rats in both stroke groups and the normal
aged rats were weighed, and evaluated on a 3 point score for activity level (1=sick, 2=low
activity, 3=normal activity) and coat condition (1=dirty and rough, 2=moderate, 3=
smooth and shiny) at least once per week. (A) Both stroke groups had lower weights than
the normal aged group, but there was no difference between the two stroke groups
(p<0.005, repeated measures ANOVA, Bonferroni test for post-hoc comparison). (B)
There were no differences between groups for activity level. (C) There were no
differences between groups for coat condition. Error bars denote ± standard error of the
mean.
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Stroke Lesion Size

A

B

Figure 8. Stroke lesion size. (A) Representative right sided stroke lesion one day poststroke in an aged rat (scale bar=1 cm). In the TTC (2,3,5-triphenyl-2H-tetrazolium
chloride)-reacted coronal brain sections viable tissue appears red and the ischemic
infarction appears white demonstrating sensorimotor cortex involvement and subcortical
sparing. (B) The stroke lesion size, represented as percent of the intact hemisphere, did
not differ between the two stroke groups (p=0.706, t-test). Error bars denote ± standard
error of the mean.
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Ratio of Right to Left Hippocampal Areas

Figure 9. Ratio of Right to Left Hippocampal Areas. Analysis by a one-way ANOVA
found a significant effect for group (p<0.05), and post-hoc analysis by the StudentNewman-Keuls test showed that the normal aged group and stroke/control antibody
group were significantly different (p<0.05). Error bars denote ± standard error of the
mean. *p<0.05.

77
Place Task Mean Time and Distance to Locate the Hidden Platform
During the Place Task
A

B

Figure 10. Place task mean time and distance to locate the hidden platform. (A)
Analysis by a repeated measures ANOVA of time to locate the hidden platform found a
significant effect for group (p=0.044) and post hoc analysis by the Bonferroni test
showed that the stoke/control antibody group took significantly more time to locate the
platform than normal aged rats (p=0.043). The stroke/anti-Nogo-A antibody group was
not significantly different from the normal aged group (p=0.258) or the stroke/control
antibody group (p=1.000). (B) Analysis by a repeated measures ANOVA of distance to
locate the hidden platform did not find a significant effect for group (p=0.064), so there
was not a significant difference between the three groups for distance to located the
hidden platform. Error bars denote ± standard error of the mean. *p<0.05. (Figure
discussed in methods statistical analysis section).
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Rate to Acquire the Location of the Hidden Platform During the Place Task

Figure 11. Improved performance on a spatial reference memory task after stroke
and treatment with anti-Nogo-A immunotherapy. (A) Time to locate the hidden
platform during the Morris water maze place task. Average curves of the fitted functions
for each group. (A’) Averages of the individual parameters of the functions. Time at the
start of testing, or the y intercept, was the same for all groups. As testing continued
normal aged and stroke/anti-Nogo-A antibody treated rats acquired the location of the
platform faster than stroke/control antibody treated rats, as shown by the slope parameter
(p < 0.001, likelihood based χ2 test of random-effects simple exponential two-parameter
model, η ( x) = θ1e −θ 2 x , where x = day – 1). (B) Distance to locate the hidden platform
during the Morris water maze place task. Average curves of the fitted functions for each
group. (B’) Averages of the individual parameters of the functions. Distance at the start
of testing, or the y intercept, was the same for all groups. As testing continued all three
groups acquired the location of the platform at significantly different rates, with the
stroke/anti-Nogo-A antibody treated rats having faster rates to acquire the platform
location than stroke/control antibody treated rats (p<0.001 for stroke/anti-Nogo-A
antibody and stroke/control antibody, p<0.01 for normal aged and stroke/anti-Nogo-A
antibody, p<0.001 for normal aged and stroke/control antibody, likelihood based χ2 test
of random-effects simple exponential two-parameter model, η ( x) = θ1e −θ 2 x , where x = day
–1). Error bars denote ± standard error of the mean. **p<0.01, ***p<0.001.
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Swim Velocity During the Place Task

Figure 12. Swim velocity during the Morris water maze place task did not significantly
differ across groups (p=0.2476, repeated measure ANOVA). Error bars denote ± standard
error of the mean.
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Probe Trial

Figure 13. Probe Trial. During the probe trial all groups equally preferred the quadrant
that contained the platform during the place task (p=0.876, one-way ANOVA). Error bars
denote ± standard error of the mean.
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Matching-to-Place Task

Figure 14. Matching-to-Place Task. During the matching-to-place task all groups found
the platform faster on Trial 2 than on Trial 1 (p<0.001), and there were no significant
differences between groups (p=0.4387 for trial 1, p=0.0550 for trial 2, two-way repeated
measures ANOVA). Error bars denote ± standard error of the mean.
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Thigmotaxis

Figure 15. Thigmotaxis. (A) Thigmotaxis, time spent in the periphery, during the place
task. Average curves of the fitted functions for each group. (A’) Averages of the
individual parameters of the functions. Thigmotaxis at the start of testing, or the y
intercept, was the same for all groups. As testing continued both stroke groups showed
more thigmotaxis behavior than normal aged rats (p<0.001, likelihood based χ2 test of
random-effects simple exponential three-parameter model, η ( x ) = θ1e −θ 2 x + θ 3 , where x =
day – 1). Thigmotaxis at the end of testing, or the lower asymptote, was the same for all
groups. (B) Thigmotaxis, distance swam in the periphery, during the place task. Average
curves of the fitted functions for each group. (B’) Averages of the individual parameters
of the functions. Thigmotaxis at the start of testing, or the y intercept, was the same for
all groups. As testing continued both stroke groups showed more thigmotaxis behavior
than normal aged rats (p<0.001, likelihood based χ2 test of random-effects simple
exponential three-parameter model, η ( x ) = θ1e −θ 2 x + θ 3 , where x = day – 1). Thigmotaxis
at the end of testing, or the lower asymptote, was the same for all groups. Error bars
denote ± standard error of the mean. ***p<0.001.
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Path Circuity

Figure 16. Path Circuity. The path circuity or direct distance to the platform/ the actual
distance swam to the platform during a trial during the place task. Both stroke groups had
significantly more circuitous paths than the normal aged group (p<0.05, repeated
measures ANOVA, Bonferroni test for post-hoc comparison). Error bars denote ±
standard error of the mean. *p<0.05.
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Swim Paths for a Normal Aged Rat for the Place Task

Figure 17. Swim Paths for a normal aged rat during seven days of place task testing.
The start location is marked by a black dot, and the hidden platform is marked by a blue
square.
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Swim Paths for a Normal Aged Rat for the Probe Trial,
and Matching-to-Place Task

Figure 18. Swim Paths for a normal aged rat during the probe trial and five days of
matching-to-place testing. The start location is marked by a black dot, and the hidden
platform is marked by a blue square.
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Swim Paths for a Stroke/Control Antibody Rat for the Place Task

Figure 19. Swim Paths for a stroke/control antibody rat during seven days of place
task testing. The start location is marked by a black dot, and the hidden platform is
marked by a blue square.
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Swim Paths for a Stroke/Control Antibody Rat for the Probe Trial,
and Matching-to-Place Task

Figure 20. Swim Paths for a stroke/control rat during the probe trial and five days
of matching-to-place testing. The start location is marked by a black dot, and the hidden
platform is marked by a blue square.
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Swim Paths for a Stroke/Anti-Nogo-A Antibody Rat for the Place Task

Figure 21. Swim Paths for a stroke/anti-Nogo-A antibody rat during seven days of
place task testing. The start location is marked by a black dot, and the hidden platform is
marked by a blue square.

89
Swim Paths for a Stroke/Anti-Nogo-A Antibody Rat for the Probe Trial,
and Matching-to-Place Task

Figure 22. Swim Paths for a stroke/anti-Nogo-A antibody rat during the probe trial
and five days of matching-to-place testing. The start location is marked by a black dot,
and the hidden platform is marked by a blue square.
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Angular Variance at the Start of the Place Task Trials

Figure 23. Angular variance at the start of place task trials. Heading direction angle
represents the actual trajectory of the rat in relation to a direct trajectory to the platform.
Angular variance or the length of the mean vector (r) represents the spread of the angles.
There were no significant differences between the three groups when comparing the
angular variances for individual rats across the seven days of the place task (p=0.345,
repeated measures ANOVA). Error bars denote ± standard error of the mean.
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Heading Directions at the Start of the Place Task Trials

*
*

Figure 24. Heading directions at the start of the place task trials. The mean heading
direction angles from the four daily trials for each rat are represented above as dots. The
group mean heading direction angles for each day are represented as colored lines. The
length of the line represents the angular variance, with longer lines having less variance.
On day two the mean angle from the stroke/control antibody treated rats significantly
differed from the stroke/anti-Nogo-A antibody treated rats (p<0.05, Watson-Williams F
test). *p<0.05.
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Representative Golgi-Cox Stained Hippocampal Neurons

Figure 25. Representative Golgi-Cox stained hippocampal CA3 (A) and CA1 pyramidal
cells (B) and dentate gyrus granule cell (C, white arrows), and the corresponding
Neurolucida tracings (A’, B’, C’). Images were acquired from the hippocampus of a
normal aged rat. Scale bar=100 µm.
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CA3 Pyramidal Cell Dendritic Tree Complexity

Figure 26. Decreased dendritic arbor complexity of CA3 pyramidal cells in both
stroke groups ipsilateral to the stroke. (A) Quantification of apical total number of
branch segments and total dendritic length, and (A’) apical branch segments and dendritic
length in each branch order. (B) Quantification of basilar total number of branch
segments and total dendritic length, and (B’) basilar branch segments and dendritic length
in each branch order. Error bars denote ± standard error of the mean. *p<0.05, ** p<0.01,
***p<0.001 for normal aged vs. both stroke groups, and #p<0.05 for normal aged vs.
stroke/control antibody (one-way ANOVA p values reported, Student-Newman-Keuls
test for post-hoc comparison).
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CA1 Pyramidal Cell Dendritic Tree Complexity

Figure 27. Decreased dendritic arbor complexity of CA1 pyramidal cells in both
stroke groups ipsilateral to the stroke. (A) Quantification of apical total number of
branch segments and total dendritic length, and (A’) apical branch segments and dendritic
length in each branch order. (B) Quantification of basilar total number of branch
segments and total dendritic length, and (B’) basilar branch segments and dendritic length
in each branch order. Error bars denote ± standard error of the mean. #p<0.05 for normal
aged vs. stroke/control antibody (one-way ANOVA p value reported, Student-NewmanKeuls test for post-hoc comparison). ‡p<0.05 for normal aged vs. stroke/anti-Nogo-A
antibody (Kruskal Wallis one-way ANOVA on ranks p value reported, Dunn’s method
for post-hoc comparison).
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Dentate Gyrus Granule Cell Dendritic Tree Complexity

Figure 28. Decreased dendritic arbor complexity of dentate gyrus granule cells in
the stroke/control antibody group ipsilateral to the stroke. (A) Quantification of total
number of branch segments and total dendritic length, and (A’) branch segments and
dendritic length in each branch order. Error bars denote ± standard error of the mean.
##p<0.01 for normal aged vs. stroke/control antibody (Kruskal Wallis one-way ANOVA
on ranks p value reported, Dunn’s method for post-hoc comparison).
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CA3 and CA1 Pyramidal Cell Apical Dendritic Spine Density and Morphology

Figure 29. Apical dendritic spine density and morphology in CA3 and CA1
pyramidal cells did not significantly differ across groups. (A) Quantification of CA3
pyramidal cell dendritic spine density, and (B) CA3 pyramidal cell dendritic protrusion
morphology. (C) Quantification of CA1 pyramidal cell dendritic spine density, and (D)
CA1 pyramidal cell dendritic protrusion morphology. Error bars denote ± standard error
of the mean.
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DISCUSSION
The results from the present study show that anti-Nogo-A immunotherapy given one
week following stroke in aged rats improved performance on the Morris water maze
place task. However, improvement was not correlated with anatomical changes in
dendritic arbors of hippocampal CA3 and CA1 pyramidal, dentate gyrus granule cells or
dendritic spines of CA3 and CA1 pyramidal cells.
Previous studies have shown that anti-Nogo-A immunotherapy and the
NgR(310)Ecto-Fc protein, which binds to the ligands of the Nogo-66 receptor (NgR1)
and thereby blocks receptor activation, are effective up to one week after stroke in rats in
inducing recovery of sensorimotor function in the stroke-impaired forelimb
(Papadopoulos et al., 2002a; Wiessner et al., 2003a; Lee et al., 2004; Seymour et al.,
2005a; Tsai et al., 2007). Furthermore, improvement on a sensorimotor task has been
shown in aged rats after stroke given anti-Nogo-A immunotherapy, although the recovery
took longer to occur as compared to adult rats (Markus et al., 2005a). The sensorimotor
recovery was correlated in adult rats with axonal sprouting from intact pathways across
the midline into subcortical denervated areas (Papadopoulos et al., 2002a; Wiessner et al.,
2003a; Lee et al., 2004; Seymour et al., 2005a), and dendritic sprouting and increased
dendritic spine density in the contralesional sensorimotor cortex (Papadopoulos et al.,
2006). Further support for the role of Nogo-A in recovery from stroke is provided from
genetic studies using knock-out models. Mice that lack the NgR1 or that lack Nogo-A
and Nogo-B have improved sensorimotor recovery after a photothrombotic lesion to the
sensorimotor cortex as compared to heterozygous littermates, and this correlates with
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axonal sprouting from intact pathways across the midline into the denervated red nucleus
and spinal cord (Lee et al., 2004).
In the present study we show improved performance on a spatial memory task
after stroke in aged rats given anti-Nogo-A immunotherapy one week post-stroke.
Several studies examining the therapeutic use of anti-Nogo-A immunotherapy to improve
cognitive impairment in rodent brain injury models support our findings. In an
experimental model of traumatic brain injury, adult rats that sustained a lateral fluid
percussion injury and treatment with anti-Nogo-A immunotherapy starting 24 hours postinjury showed improved performance on the Morris water maze place task (Lenzlinger et
al., 2005a; Marklund et al., 2007b). In that study, rats with traumatic brain injury given
anti-Nogo-A immunotherapy had a higher expression of GAP-43 in CA1 of the
hippocampus as compared to rats with traumatic brain injury and treated with control
antibody (Marklund et al., 2007b). The higher levels of GAP-43 suggest that anti-NogoA immunotherapy may enhance the axonal growth potential of the hippocampus after
traumatic brain injury. Additionally, after aspiration of the medial agranular cortex in a
model of severe neglect adult rats treated with anti-Nogo-A immunotherapy immediately
post-injury showed improvement from neglect. These behavioral improvements could be
abolished by severing the corpus callosum causing the rats to once again exhibit severe
neglect, and demonstrating the importance of the contralateral hemisphere in the
behavioral recovery (Brenneman et al., 2008a). Interestingly, genetically modified
unlesioned mice that lack Nogo-A have normal spatial memory on the Morris water maze
but have enhanced motor coordination and balance as compared to heterozygous
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littermates (Willi et al., 2008a). Our study adds to the growing body of literature of
cognitive recovery with anti-Nogo-A immunotherapy by using the clinically relevant age
group and time of treatment.
Due to the importance of the hippocampus for performance of spatial memory
tasks (D'Hooge et al., 2001a), and the correlation of anti-Nogo-A immunotherapy with
dendritic sprouting (Papadopoulos et al., 2006), we investigated whether the improved
performance we found in the spatial reference memory task with anti-Nogo-A
immunotherapy post-stroke would correlate with structural changes in the hippocampus.
However, we found no differences in dendritic branching of CA3 and CA1 pyramidal and
dentate gyrus granule cells, and no differences in spine density and morphology in CA3
and CA1 pyramidal cells between rats with stroke given anti-Nogo-A immunotherapy or
given control antibody. This could be explained in several ways. First, morphological
axonal or dendritic changes in brain areas other than the hippocampus may underlie the
improved performance in the spatial memory task after anti-Nogo-A immunotherapy.
Performance on the Morris water maze depends upon a distributed network of brain areas
(D'Hooge and De Deyn, 2001a) that have neural activity in response to place, including
the medial entorhinal cortex, striatum, subiculum and lateral septum (Knierim, 2006),
areas which were not examined in this study. Interestingly, when rats received non-spatial
pre-training to become familiar with the Morris water maze, blocking NMDA receptordependent LTP in the dentate gyrus did not result in impairment (Saucier et al., 1995).
These studies suggest that, although the hippocampus is important for Morris water maze
performance, other brain regions also contribute to performance on the Morris water
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maze. Secondly, although dendritic growth was examined quite extensively in CA3, CA1
and the dentate gyrus, we did not investigate axonal growth in the hippocampus, raising
the possibility that axonal growth may underlie the improved performance on the spatial
memory task after anti-Nogo-A immunotherapy. Axonal growth in the hippocampus has
been shown after treatment with anti-Nogo-A antibodies in cholinergic axons after
damage to the septo-hippocampal pathway (Cadelli et al., 1991a) and in hippocampal
slice cultures either intact or after cutting the Schaffer collaterals (Craveiro et al., 2008a),
or perforant pathway (Mingorance et al., 2004b). Finally, we cannot rule out that nonmorphological changes affecting factors such as electrophysiological characteristics or
biochemical composition of hippocampal cells, or cells in other areas of the brain
important for spatial memory may underlie the improved performance on the spatial
memory task after anti-Nogo-A immunotherapy.
Previous studies have shown that unilateral MCAO impairs performance on the
Morris water maze place task in adult (Yonemori et al., 1999; Dahlqvist et al., 2004) and
aged rats (Andersen et al., 1999), as we also show in our study. Aging alone also causes
impaired performance on the Morris water maze place task (Lindner, 1997; Andersen et
al., 1999). Despite the consistent demonstration of impaired performance on the Morris
water maze after unilateral MCAO by us and others and the importance of the
hippocampus for performance on the Morris water maze, the MCAO does not cause gross
histological damage to the hippocampus (Yonemori et al., 1999). Here we show a subtle
decrease in dendritic complexity in CA3, CA1 and dentate gyrus neurons of the
ipsilesional hippocampus. This is in contrast to a study of dendritic complexity after
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transient global cerebral ischemia in rats, a model which causes neurodegeneration in
CA1. In this study, 22 days post transient global cerebral ischemia, CA2/CA3 neurons
were found to have increased dendritic volume, surface density of dendritic membrane,
and number of synapses per neuron (Briones et al., 2006). Therefore, unilateral MCAO
can cause decreased dendritic complexity in the ipsilesional hippocampus, while transient
global cerebral ischemia can cause increased dendritic complexity in the hippocampus in
non-degenerative cells.
Additional studies have examined the hippocampus after unilateral MCAO. One
study reported an increase in the NMDA receptor subunit NR2B mRNA in the
ipsilesional dentate gyrus, an increase in synapsin II bilaterally in the dentate gyrus, and a
decrease in NGFI-A mRNA bilaterally in CA3 as compared to naive animals (Dahlqvist
et al., 2004), suggesting that unilateral MCAO can effect gene expression in the
hippocampus. On the other hand, another study of unilateral MCAO found no significant
differences in the CA1 subregion of the hippocampus in LTP, microtubule-associated 2
positive fibers, and glial fibrillary acidic protein (GFAP) positive cells between the
contralesional and ipsilesional sides (Okada et al., 1995). Furthermore, this study found
no changes in acetylcholine levels in the dorsal and ventral hippocampus in rats after
MCAO as compared to sham operated rats and intact rats. Therefore, unilateral MCAO
appears to cause gene expression changes in the hippocampus.
In this study we found that rats with stroke, regardless of antibody treatment,
spent more time swimming near the wall of the pool, i.e. thigmotaxis, and took less direct
routes to the platform during the place task than normal aged rats. When we analyzed the
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trajectory rats took at the start of place task trials, there were no differences in angular
variance, and only slight differences in mean angle between groups. This suggests rats
with stroke are using different navigational strategies during the Morris water maze task,
but that their starting trajectory is similar to normal aged rats. Thigmotaxis is considered
a maladaptive behavior because the hidden platform is never located near the wall.
Increases in thigmotaxis behavior have previously been reported after permanent MCAO
(Yonemori et al., 1999; Dahlqvist et al., 2004), and in aged animals as compared to adult
animals (Andersen et al., 1999). Yonemori et al. (1999) reported that thigmotaxis
behavior was correlated with shrinkage of the caudate-putamen, suggesting that damage
to the caudate-putamen plays a role in thigmotaxis. It is possible that our model of
MCAO could have caused ischemia and damage to the caudate-putamen. Thigmotaxis
behavior has also been described in human subjects in a virtual maze task and in a real
maze task. In these studies thigmotaxis behavior was correlated with lower performance
on the spatial learning task, underperformance on working memory and spatial
construction tests, and higher levels of fear (Kallai et al., 2005; Kallai et al., 2007). These
results suggest that, although aged rats treated with anti-Nogo-A immunotherapy poststroke are performing better on the Morris water maze than control antibody treated rats,
they are not performing the task in the same manner as a non-stroke aged rat.
Neglect may have played a role in the Morris water maze performance of the aged
rats from this study. As mentioned previously, damage to the medial agranular cortex
causes neglect in rats (Brenneman et al., 2008b). Additionally, damage to the posterior
parietal cortex can also cause neglect in rats (Reep et al., 2009) and this latter cortical
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region is often perturbed in our model of MCAO. However, as rats in this study were not
behaviorally evaluated for neglect, we are unable to say whether the MCAO caused
neglect, or if the anti-Nogo-A immunotherapy had any affects on any potential neglect.
In conclusion, in the present study we found improved performance on the Morris
water maze reference memory task after stroke and anti-Nogo-A immunotherapy in the
aged, thereby providing evidence that anti-Nogo-A immunotherapy may have potential as
a treatment for cognitive impairment after stroke in the aged.

CHAPTER FOUR
RECOMBINANT ADENO-ASSOCIATED VIRUS 2/8 MEDIATED NOGO-A
KNOCKDOWN IN AGED RATS DOES NOT ALTER DENDRITIC SPINES
ABSTRACT
Nogo-A is most widely known as a myelin axonal growth inhibitor, but Nogo-A
is also found in many populations of neurons where it may have distinct functions
different from growth inhibition. We have previously shown that AAV2/8 mediated
Nogo-A knockdown in neonatal rat cortical neurons led to decreased dendritic spine
density and an increased percentage of dendritic spines with an immature morphology.
Aged rats underwent injection of the AAV2/8 vector bilaterally into the dorsal
hippocampus to deliver an shRNA to knockdown Nogo-A. Four weeks later the rats were
sacrificed and brains processed for confocal imaging and dendritic spine analysis. We
found that AAV2/8 mediated knockdown of Nogo-A in the aged rat hippocampus does
not alter dendritic spine density or morphology in CA1 pyramidal cell apical dendritic
trees. Taken together, these data suggest that neuronal Nogo-A may play disparate roles
in synaptic structural plasticity in different neuronal populations.
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INTRODUCTION
The Nogo-A protein, well described as a myelin growth inhibitor (Gonzenbach
and Schwab, 2008), is found in oligodendrocyte myelin sheaths (Wang et al., 2002c) and
in many CNS neurons (Wang et al., 2002c; Hunt et al., 2003; Buss et al., 2005) and has
emerged as an important therapeutic target in several neurological disorders such as
stroke and spinal cord injury. When anti-Nogo-A immunotherapy is given to rats one
week after stroke, performance on a skilled sensorimotor test (Papadopoulos et al.,
2002a; Markus et al., 2005a; Seymour et al., 2005a; Tsai et al., 2007) is improved, and in
adult rats this improvement is correlated with axonal compensatory growth
(Papadopoulos et al., 2002a; Markus et al., 2005a; Seymour et al., 2005a) and dendritic
plasticity in the contralesional sensorimotor cortex (Papadopoulos et al., 2006). AntiNogo-A immunotherapy also leads to cognitive recovery after experimental brain injury
models such as traumatic brain injury (Lenzlinger et al., 2005a; Marklund et al., 2007b)
and severe neglect (Brenneman et al., 2008a) in rats. After unilateral cervical spinal cord
injury in adult Macaque monkeys anti-Nogo-A immunotherapy improved recovery of
hand dexterity, and this recovery was correlated with axonal compensatory growth
(Freund et al., 2006; Freund et al., 2007b; Freund et al., 2009). Evidence also suggests
that Nogo-A may be important in Alzheimer ’s Disease and temporal lobe epilepsy. The
Nogo-A protein has altered expression in the hippocampal neurons of patients who had
Alzheimer’s Disease (Gil et al., 2006b) and temporal lobe epilepsy (Bandtlow et al.,
2004; Gil et al., 2006b), and is associated with beta-amyloid deposits in patients who had
Alzheimer ’s Disease (Gil et al., 2006b). For all of these reasons, understanding the role
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of Nogo-A in growth inhibition and the exact role that it plays in neuronal function may
lead to new therapeutic avenues for treating various neurological disorders.
Current evidence suggests that neuronal Nogo-A has additional functions in
addition to axonal growth inhibition (Montani et al., 2009). For example, immunogold
labeling of Nogo-A demonstrated particles near to the post-synaptic density (Liu et al.,
2003), and knocking down Nogo-A in neonatal cortical neurons led to reduced dendritic
spine density and an increased percentage of immature spine morphologies (Pradhan,
2007). Because of the altered expression of Nogo-A in hippocampal neurons in several
neurological diseases and because of these potential additional roles for neuronal Nogo-A
in synaptic structural plasticity, we sought to knockdown Nogo-A in the hippocampus of
aged rats and assess changes in dendritic spines morphology. We injected an AAV2/8
vector bilaterally into the dorsal hippocampus to deliver a shRNA to knockdown NogoA. The AAV2/8 vector was chosen to deliver the shRNA sequence because it can support
persistent transgene expression for chronic experiments, and the host immune response to
AAV is minimal (Daya and Berns, 2008). Reduction of Nogo-A levels is obtained by
utilizing the endogenous RNAi machinery of the cell by which short double stranded
RNA is incorporated into the RNA-induced silencing complex (RISC) and leads to
sequence specific downregulation of homologous mRNA translation (Castanotto et al.,
2009a). This method of gene silencing is advantageous over knock-out models for
studying the function of a gene in adult or aged animals, because it avoids the possible
confounding effects of silencing the gene during development, when it may have
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different functions. Additionally, knock-out models are more likely to have compensatory
mechanisms such as upregulation of another gene.
We found that knocking down Nogo-A in CA1 pyramidal cells of aged rats did
not alter dendritic spine density or morphology.

METHODS
AAV Constructs
Plasmids were constructed as previously described by (Pradhan, 2007). Expression
cassettes flanked by AAV2 inverted terminal repeats were packaged into AAV8 capsids.
Briefly, the control EGFP plasmid was generated by inserting the EGFP cDNA into the
Xhol and BgIll restriction sites in pAAV-MCS (Stratagene, La Jolla, CA, USA). The
Nogo-A knockdown plasmid was generated by annealing the oligonucleotides
corresponding to 856-874 of the rat Nogo-A cDNA into the Bbs1 and Xba1 site of the
mU6pro plasmid, and then inserting the resulting fragment into the pAAV-EGFP plasmid
at the MIuI site upstream of the CMV promoter.
Plasmids were packaged as previously described by (Pradhan, 2007) using a
Virapack transfection kit (Stratagene). The AAV2 inverted terminal repeat constructs
were co-transfected in AAV-293 cells with p5E-VD282, and pHelper plasmids
(Stratagene). Purification by iodixanol step gradient was followed by centrifugation to
concentrate and desalt (Biomax 100K concentrator, Millipore, Bedford, MA, USA). For
titer estimation EGFP positive cells were counted 72 hours after serial dilutions and
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infection of HT1080 cells. Titers for both the AAV-EGFP, and AAV-shNogo856 were 2
×109 infectious particles (iu)/ml.

Animal Subjects
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Aged male Fischer 344 rats (21-22 months of age at
start of study) were divided into two groups: (1) control AAV-EGFP (n=10, 6 used for
dendritic spine analysis), and (2) AAV-shNogo856 (n=9, 8 used for dendritic spine
analysis). In the AAV-EGFP 4 animals were dropped from dendritic spine analysis. Two
died due to aged related complications, and two had misplaced injection locations. In the
AAV-shNogo856 group one animal was dropped from dendritic spine analysis due to
misplaced injection locations. Animals were single housed and were maintained in a 12
hour light/dark cycle, with free access to food and water.

Intracranial Injection Surgery
The experimental design is depicted in Fig 30. Rats were anesthetized with isoflurane
inhalant anesthesia (3% in oxygen) and secured in a rat stereotaxic frame. The skull was
exposed through a midline incision in the scalp, and the head was aligned and leveled
using a rat alignment tool (David Kopf Instruments, Tujunga, CA, USA). The appropriate
virus was injected bilaterally into the dorsal hippocampus using a 32 gauge needle, a 5 µl
or 10 µl syringe (Hamilton, Reno, NV, USA), and a microsyringe pump (UtraMicroPump
with SYS-Micro4 controller, World Precision Instruments, Sarasota, FL, USA) at a rate
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of 0.2 µl/minute. Six rats from the AAV-EGFP group and 7 rats from the AAVshNogo856 group were injected with 3 µl of virus on each side of the hippocampus at
coordinates 2.35 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm ventral (1.5 µl for
each depth), relative to bregma. Due to small lesions at the injection sites the final 4 rats
in the AAV-EGFP group (2 used for dendritic spine analysis), and 2 rats from the AAVshNogo856 group (2 used for dendritic spine analysis) were injected with less virus, 1 µl
of virus, on each side of the hippocampus at the same coordinates except at only one
depth (2.3 mm). Body temperature was maintained at 37.5º C with a heating pad and an
autotuning temperature controller connected to a rectal probe (TCAT-2, Physitemp
Instruments, Inc., Clifton, NJ, USA).

Dendritic Spine Analysis
Four weeks post-intracranial injection rats were overdosed with pentobarbital (100
mg/kg, intraperitoneal) and transcardially perfused with 0.9% saline and 10,000 U
heparin/liter followed by 4% paraformaldehyde. The brains were removed and immersed
whole in 4% paraformaldehyde for 1 hour, and then transferred to 30% sucrose for three
days. Brains were frozen in isopentane on dry ice at -25º C and then stored at -80º C until
there were sectioned coronally on a cryostat at 50 µm. Our experiments with AAV
transduction in neonatal rats used 200 µm sections taken on the vibratome, but we found
that we were unable to image dendritic spines when we processed the aged tissue in this
way. Alternate free floating sections were reacted with cupric sulfate 2.5 mM in
ammonium acetate 50 mM buffer for 15 minutes to reduce lipofuscin autofluorescence as
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described by Schnell et al.(1999). Sections were then mounted to slides and coverslipped
with Dako fluorescence mounting media (Dako North America, Inc., Carpinteria, CA,
USA).
Dorsal hippocampal CA1 pyramidal cell apical dendrites in the stratum radiatum
layer were analyzed for dendritic spine density and morphology. For selection the
dendritic tree of a cell had to be well filled with EGFP. Thin optical sections (.9 µm) of
first order or higher dendrites were acquired with a Zeiss 510 laser scanning microscope
(488 nm laser, pinhole 112) and a 60x objective (1.2 N.A. water corrected), and 4x zoom.
For each dendrite, 10 µm segments were identified using NIH ImajeJ software and for
inclusion the segment had to be at least 10 µm from the branch point. For each segment
dendritic protrusions were counted and assigned to a morphology of filopodia, thin,
stubby, mushroom or 2-headed as described by Bourne and Harris (2008). Additionally,
the length and head diameters of each protrusion were measured. Five dendritic segments
were analyzed per brain.

Immunostaining
Alternate free floating sections were selected for immunostaining of Nogo-A (Cheatwood
et al., 2008) and glial fibrillary acidic protein (GFAP). Sections were blocked for 1 hour
at room temperature with 10% normal goat serum (NGS), and 0.25% Triton-X 100
(TX100) in 0.01 M phosphate buffered saline (PBS). Next the sections were incubated
overnight at 4º C with either purified mouse monoclonal anti-Nogo-A antibody (11C7) or
the rabbit polyclonal anti-GFAP (Sigma, St. Louis, MO, USA) at 1:500 with 5% NGS
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and 0.25% TX100 in PBS. After washing, sections were incubated for 1 hour at room
temperature with the appropriate secondary antibody, either Alexa Fluor 594 goat antimouse or tetramethylrhodamine goat anti-rabbit (Invitrogen, Carlsbad, CA, USA), at
1:1000 with 5% NGS and 0.25% TX100 in PBS. Next, sections were washed and reacted
with cupric sulfate as described above to reduce lipofuscin autofluorescence. Sections
were then mounted to slides and coverslipped with Dako fluorescence mounting media.
Thin optical sections (1 µm) were acquired with a Zeiss 510 laser scanning microscope
(561 and 488 nm lasers, pinhole 80 and 84) and a 40x objective (1.2 N.A. water
corrected), and 1x zoom. Using the same settings sections (13.1 µm) were also acquired
with a 10x objective. For comparison of Nogo-A expression levels optical sections were
acquired at the same detector gain and amplifier offset.

Statistical Analysis
For analysis of dendritic spine data t-tests were used, and when the data were not normal
the Mann-Whitney Rank Sum Test was used (SigmaStat, Systat, San Jose, CA, USA).
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Experimental Timeline

Figure 30. Experimental timeline. Aged rats underwent bilateral intra-hippocampal
injections of AAV-EGFP or AAV-shNogo856. Four weeks post-injection rats were
sacrificed and the brains processed for confocal imaging.
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RESULTS
Nogo-A knockdown reduced the levels of the Nogo-A protein in CA1 pyramidal cells
To confirm knockdown of the Nogo-A gene in aged rats by AAV mediated delivery of
shNogo856, we immunostained alternate sections for Nogo-A expression. Nogo-A
immunoreactivity in transduced CA1 pyramidal cells was markedly reduced in the AAVshNogo856 rats (Fig 35D-F, 36D-F) when compared to control AAV-EGFP rats (Fig
35A-C, 36A-C). Therefore, AAV mediated delivery of shNogo-856 effectively reduced
the expression of Nogo-A in CA1 pyramidal cells of aged rats. Furthermore, the shRNA
used in these experiments has been shown previously to effectively reduce the levels of
Nogo-A gene expression both in vitro and in vivo in neonatal rats (Pradhan, 2007).

Nogo-A knockdown did not alter dendritic spine density and morphology in CA1
pyramidal cells
EGFP filled apical dendrites of hippocampal CA1 pyramidal cells were analyzed for
dendritic spine density and morphology. Mean dendritic spine density in the AAVshNogo856 group was 9.8 spines per 10 µm and in the control AAV-EGFP group was
11.47 spines per 10 µm, and dendritic spine density did not significantly differ between
the groups (p= 0.230; Fig 32A). In order to examine dendritic protrusion morphology we
subjectively assigned each dendritic protrusion analyzed to a morphology of thin, stubby,
mushroom, two-headed or filopodial (Fig 31A, Bourne and Harris, 2008). In both groups
the most common morphology was stubby, followed by thin, mushroom and filopodial
(Fig 32B). The number of protrusions for each of the morphologies did not significantly
differ between the AAV-shNogo856 group and the control AAV-EGFP group (p= 0.176
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for filopodium, p=0.426 for thin, p=0.531 for stubby, p=0.459 for mushroom; Fig 32B).
In addition, we quantified the length and head diameter of each dendritic protrusion
analyzed (Fig 31B). Mean dendritic spine length in the AAV-shNogo856 group was 0.57
µm and in the control AAV-EGFP group was 0.61µm (Fig 33A). Mean dendritic spine
head diameter in the AAV-shNogo856 group was 0.38 µm and in the control AAV-EGFP
group was 0.39 µm (Fig 34A). Spine length and head diameter did not significantly
differ between the AAV-shNogo856 group and the control AAV-EGFP group (p=0.214
for spine length, p=0.475 for head diameter; Fig 33A, 34A). Furthermore, when we
analyzed length and head diameter by morphology and included filopodial forms, we
found no significant differences between the AAV-shNogo856 group and the control
AAV-EGFP group ( p=0.358 for filopodial length, p=0.122 for thin length, p=0.626 for
stubby length, p=0.308 for mushroom length, p=0.382 for filopodial head diameter,
p=0.491 for thin head diameter, p=0.466 for stubby head diameter, p=0.764 for
mushroom head diameter; Fig 33B, 34B). Therefore, Nogo-A knockdown in aged rats
does not affect morphology or density of dendritic protrusions in CA1 pyramidal cells.

AAV intra-hippocampal injection in aged rats caused EGFP positive astrocytes and
dose-dependent tissue disruption at the injection site
To start we injected 3 µl of either AAV-EGFP or AAV-shNogo856 bilaterally into the
dorsal hippocampus at a titer of 2 × 109 infectious units (iu)/ml. Four weeks later when
the animals were sacrificed, we found robust expression of the EGFP reporter transgene
in CA1 pyramidal cells, dentate gyrus granule cells and CA3 pyramidal cells (Fig 37A).
We also saw cells of a non-neuronal morphology containing EGFP dispersed throughout
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the hippocampus. Immunostaining for GFAP showed that many of these cells containing
EGFP of non-neuronal morphology were astrocytes (Fig 37). Additionally, we saw
microlesions at many of the injections sites (present in 50% of AAV-EGFP brains, and
100% of AAV-shNogo856 brains), which were focused in the area of the dentate gyrus
and were found in both rats with AAV-EGFP injections and AAV-shNogo856 injections
(Fig 37A-C). The cells containing EGFP of non-neuronal morphology, many of which
were astrocytes, were concentrated around the microlesions. To determine if the
microlesions were dose-dependent we injected an additional 6 animals with 1 µl of either
AAV-EGFP (4 rats) or AAV-shNogo856 (2 animals) bilaterally into the dorsal
hippocampus at a titer of 2 × 109 iu/ml. Four weeks later when the animals were
sacrificed, we found robust expression of the EGFP reporter transgene in hippocampal
neurons, and by rough visual examination there appeared to be fewer transduced cells
than in animals with the higher dose, though we did not quantify this. Four of the six
animals had well filled CA1 pyramidal neurons so these animals were included in
dendritic spine analysis. None of the animals with the lower dose had microlesions at the
injection site. In the animals with the lower dose cells containing EGFP of a nonneuronal morphology were still present. Therefore, AAV-EGFP and AAV-shNogo856
intra-hippocampal injections in aged rats caused dose-dependent microlesions at the
injection sites, and cells to contain EGFP-positive cells of non-neuronal morphology,
many of which were astrocytes.
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Representative EGFP Filled Dendrite Segment
A

B

Figure 31. CA1 pyramidal cell apical dendrite segment. (A) Example of a first order
apical dendrite segment. Scale Bar =5 µm. (B) Enlargement of a mushroom spine to show
how spine length and spine head diameter were delineated. Scale Bar= 1 µm.
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CA1 Pyramidal Cell Apical Dendritic Protrusion Density
A

B

Figure 32. CA1 pyramidal cell dendritic protrusion density is unaltered after NogoA knockdown. (A) Quantification of dendritic spine density (excluding filopodia), and
(B) dendritic protrusion density by morphology. Error bars denote ± standard error of the
mean.
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CA1 Pyramidal Cell Apical Dendritic Protrusion Length
A

B

Figure 33. CA1 pyramidal cell dendritic protrusion length is unaltered after Nogo-A
knockdown. (A) Quantification of dendritic spine length (excluding filopodia), and (B)
dendritic protrusion length by morphology. Error bars denote ± standard error of the
mean.
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CA1 Pyramidal Cell Apical Dendritic Protrusion Head Diameter
A

B

Figure 34. CA1 pyramidal cell dendritic protrusion head diameter is unaltered after
Nogo-A knockdown. (A) Quantification of dendritic spine head diameter (excluding
filopodia and 2-headed), and (B) dendritic protrusion head diameter by morphology.
Error bars denote ± standard error of the mean.
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Decreased Nogo-A Protein Expression after Nogo-A Knockdown

AAV-EGFP

AAV-shNogo

Figure 35. Knockdown of Nogo-A gene expression in CA1 pyramidal cells. In
animals injected with control AAV-EGFP transduced CA1 pyramidal cells expressing
EGFP show robust expression of Nogo-A, as shown by the colocalization of EGFP and
Nogo-A (C). In animals injected with AAV-shNogo856 transduced CA1 pyramidal cells
expressing EGFP show markedly reduced expression of Nogo-A, as shown by reduced
colocalization of EGFP and Nogo-A (F). Scale Bars=100 µm.
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Decreased Nogo-A Protein Expression after Nogo-A Knockdown
(High Magnification)

AAV-EGFP

AAV-shNogo

Figure 36. Knockdown of Nogo-A gene expression in CA1 pyramidal cells. In
animals injected with control AAV-EGFP transduced CA1 pyramidal cells expressing
EGFP show robust expression of Nogo-A, as shown by the colocalization of EGFP and
Nogo-A (C). In animals injected with AAV-shNogo856 transduced CA1 pyramidal cells
expressing EGFP show markedly reduced expression of Nogo-A, as shown by reduced
colocalization of EGFP and Nogo-A (F). Scale Bars=10 µm.
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Transduction of Astrocytes by AAV2/8

Figure 37. Injection of AAV-EGFP or AAV-shNogo856 at a volume of 3 µl and a titer
of 2 × 109 iu/ml often caused microlesions at the injection site in the location of the
dentate gyrus (arrow head). In addition to neurons, cells of non-neuronal morphology
were found to contain EGFP (arrows) and immunostaining of GFAP showed that many
of these cells were astrocytes (arrows). Scale Bar for A-C=200 µm, Scale Bar for D-F=20
µm .
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DISCUSSION
In the present study we successfully demonstrated neuronal transgene transfer by
AAV2/8 and RNAi mediated knockdown of Nogo-A in the hippocampus of aged rats.
However, decreasing the expression of the Nogo-A protein in the hippocampus of normal
aged rats did not affect apical dendritic spine density or morphology in CA1 pyramidal
cells.
The Nogo-A protein is most often thought of as a myelin-associated inhibitor of
axonal plasticity in the CNS. Work in our laboratory has also shown that Nogo-A can
inhibit dendritic plasticity (Papadopoulos et al., 2006). However, the Nogo-A protein is
also expressed by many neurons in the CNS by rodents (Wang et al., 2002c; Hunt et al.,
2003) and humans (Buss et al., 2005), and recent evidence suggests that neuronal NogoA may have additional functions in addition to inhibiting axonal plasticity (Montani et
al., 2009). During development the expression of Nogo-A in the brain precedes that of
the NgR (Wang et al., 2002c), a receptor that in part mediates the growth inhibitory
effects of Nogo-A. During development large projection neurons of the chick optic
tectum express Nogo-A during the process of neuritogenesis (Caltharp et al., 2007). We
have previously reported that knocking down Nogo-A during development in neocortical
pyramidal neurons led to decreased dendritic spine density and an increased percentage
of immature dendritic spine morphologies (Pradhan, 2007). This has important
consequences for synaptic transmission because dendritic spines are the main site of
excitatory synapses, and the morphology of dendritic spines relates to their function
(Bourne and Harris, 2008). Taken together, these studies of Nogo-A during development
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support the idea that neuronal Nogo-A has a role in CNS development, circuit formation,
and structural synaptic plasticity.
Further evidence points to a role in the adult for neuronal Nogo-A in synaptic
plasticity. Nogo-A is located at the post-synaptic density of spinal cord motor neurons
(Liu et al., 2003), and is located presynaptically at the neuromuscular junction (Dodd et
al., 2005). Genetic manipulation to specifically overexpress Nogo-A in adult Purkinje
cells led to the retraction and loss of inhibitory Purkinje cell terminals, suggesting a role
for neuronal Nogo-A in the maintenance of inhibitory synapses (Aloy et al., 2006). NogoA has also been shown to inhibit integrin signaling (Hu and Strittmatter, 2008), and
integrins have been implicated in regulating dendritic spine morphology (Webb et al.,
2007). The NgR1 has also been shown to be involved in synaptic plasticity. In the cortex
the NgR1 is located both pre and post-synaptically (Wang et al., 2002c), and mutant mice
without NgR1 have a shift of dendritic spine morphologies in the apical CA1 pyramidal
cell dendritic tree so there are more stubby spines and fewer mushroom and thin spines as
compared to heterozygous controls (Lee et al., 2008). This represents a shift towards
more immature dendritic spine morphologies. In this study, mice lacking NgR1 had
enhanced FGF2-dependent LTP, and attenuated LTD at hippocampal Schaffer collateralCA1 synapses. Taken together, these studies suggest that neuronal Nogo-A and its
receptor NgR1 play a role in synaptic plasticity.
Evidence suggests that neuronal Nogo-A may be important in other cellular
functions. In addition to being located on myelin sheaths (Wang et al., 2002c), and in
neurons at the synapse (Liu et al., 2003) and on the cell membrane (Dodd et al., 2005),
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Nogo-A is also found at polyribosomes, in the rough endoplasmic reticulum (Jin et al.,
2003a), throughout the dendritic trees of some neurons (Mingorance et al., 2004b), and in
axons (Wang et al., 2002c). One study showed that Nogo-A may be involved in the
shaping and stabilization of tubular endoplasmic reticulum (Voeltz et al., 2006). Another
study found that Nogo-A interacts with Nogo-B and Nogo-C, and hypothesized that they
may complex to form a channel or transporter (Dodd et al., 2005). These findings suggest
that Nogo-A has additional as of yet unidentified functions.
We chose to study the effects of knocking down Nogo-A on dendritic spines in
hippocampal CA1 pyramidal cells for several reason. Firstly, hippocampal CA1
pyramidal cells express Nogo-A both in rodents (Huber et al., 2002; Hunt et al., 2003;
Mingorance et al., 2004b) and in humans (Buss et al., 2005; Gil et al., 2006b). A study in
adult rats showed Nogo-A expression throughout the dendritic tree of CA1 pyramidal
cells (Mingorance et al., 2004b). Secondly, mice lacking the NgR1 had altered dendritic
spine morphology in the CA1 pyramidal cell dendritic tree, suggesting that Nogo-ANgR1 signaling may affect dendritic spines in CA1 pyramidal cells. Finally, neuronal
Nogo-A protein expression has been shown to be altered in the hippocampus in several
neurological diseases. Nogo-A protein is increased in hippocampal neurons of
Alzheimer’s Disease (Gil et al., 2006b), and temporal lobe epilepsy patients (Bandtlow et
al., 2004; Gil et al., 2006b). Nogo-A is also found in association with neuritic plaques in
the brains of Alzheimer ’s Disease patients (Gil et al., 2006b). We studied aged rats to
make our results more applicable to neurological diseases of aging such as Alzheimer ’s
Disease.
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The lack of observed dendritic spine structural changes in hippocampal CA1
pyramidal cells after knocking down Nogo-A can be explained several ways. First,
another protein could compensate for the reduction in Nogo-A levels. We have
previously shown in vitro knockdown of Nogo-A using the shNogo856 in the
Neuroblastoma B104 cell line does not affect the expression of Nogo-B or Nogo-C
(Pradhan, 2007). This makes it unlikely that Nogo-B or Nogo-C are compensating for the
loss of Nogo-A, but another protein that modulates synaptic structural plasticity could
compensate for the loss of Nogo-A. Secondly, the function of neuronal Nogo-A in
dendritic spine structural plasticity could differ between different neuronal types and
ages. We showed that knockdown of Nogo-A in neonatal rat cortical neurons altered
dendritic spine density and morphology (Pradhan, 2007), but neuronal Nogo-A may not
have the same affect on dendritic spines in CA1 pyramidal cells as in cortical neurons.
Finally, neuronal Nogo-A may not function in senescent neurons the same as in
developing neurons. This would explain why knocking down neuronal Nogo-A in
neonatal cortical neurons had an affect on dendritic spine structure (Pradhan, 2007),
while knocking down neuronal Nogo-A in aged CA1 pyramidal neurons did not affect
dendritic spine structure. To help elucidate the function of neuronal Nogo-A in the aged
hippocampus, further studies in aged rats with hippocampal knockdown of Nogo-A are
need to investigate hippocampal LTP and LTD, synaptic density, and the structure of the
endoplasmic reticulum.
The present study successfully used AAV2/8 for neuronal transgene transfer.
AAV serotype 8 is a promising viral vector for gene delivery to neurons in the CNS,
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because it has previously been shown to predominantly transduce neurons (Broekman et
al., 2006; Klein et al., 2006a), and has more efficient gene transfer in the rodent CNS that
some of the other AAV serotypes (Broekman et al., 2006; Harding et al., 2006; Klein et
al., 2006a). Though one study found that viral vector purification by the CsCl-gradient
method of AAV8, but not AAV9, AAV10, or AAV43, caused astrocyte transduction and
astrogliosis in the rat hippocampus, in addition to neuronal transduction (Klein et al.,
2008). However, when AAV8 was purified by iodixanol there was the expected
predominately neuronal transduction in the rats hippocampus. Therefore, Klein et al.
concluded that the CsCl purification caused AAV8 to transduce astrocytes in addition to
neurons, and they hypothesized that this was due to the higher protein and residual GFP
they found in preps purified by the CsCl-gradient method. Indeed, another study using
the CsCl purification method saw astrocyte transduction with AAV8 and AAV5 (Harding
et al., 2006). Similarly, we also found astrocytes containing EGFP, and in rats with a
higher injection dose we found microlesions at the injection sites surrounded by cells
containing EGFP of non-neuronal morphology, many of which were astrocytes. It is
likely these astrocytes were transduced by the AAV2/8, but it is also possible that the
astrocytes phagocytized the EGFP from dying transduced neurons. Though the AAV8 we
used was purified by iodixanol, this batch of vector may have had a higher protein and
residual EGFP content that usual. This would explain why we observed transduction of
both neurons and astrocytes, and astrogliosis, which may have caused microlesions at the
injection site. This illustrates that small differences in the preparation and purification of
viral vectors can alter their transduction pattern.
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In conclusion, viral mediated RNAi is a valid approach to alter the protein
expression of neurons in aged rats. However knocking down Nogo-A in the hippocampus
of aged rats did not alter the dendritic spine density or morphology of CA1 pyramidal
cells, indicating a minimal role for Nogo-A in spine density and morphology in this
population of neurons in this age group.

CHAPTER FIVE
GENERAL DISCUSSION
SUMMATION OF RESULTS
This project demonstrates that anti-Nogo-A immunotherapy improves
performance on a spatial reference memory task after sensorimotor cortical stroke in aged
rats. Aged rats with stroke and treated with anti-Nogo-A immunotherapy acquired the
location of the hidden platform in the Morris water maze place task more rapidly than
aged rats with stroke and treated with a control antibody. At the end of the place task all
groups performed equally on the probe trial, demonstrating that rats in all groups were
able to eventually learn the location of the hidden platform.
The same animals from behavioral testing were used to assess dendritic arbor
complexity and dendritic spine density and morphology of hippocampal neurons. The
results demonstrate that sensorimotor cortical stroke causes decreased dendritic arbor
complexity in the ipsilesional hippocampus, but that anti-Nogo-A immunotherapy does
not protect hippocampal neurons from these structural changes. Differences in dendritic
spine density or morphology in hippocampal neurons after stroke or anti-Nogo-A
immunotherapy were not detected.
Anti-Nogo-A immunotherapy is directed against Nogo-A on the surface of any
type of cell, including oligodendrocytes and neurons, so further studies in this dissertation
continued to investigate what role specifically neuronal Nogo-A plays in dendritic
129

130
structural plasticity in hippocampal neurons. Reduction of Nogo-A expression levels in
CA1 hippocampal neurons by RNAi did not cause detectable changes in dendritic spine
density or morphology.

THERAPEUTIC POTENTIAL OF ANTI-NOGO-A IMMUNOTHERAPY
The Nogo-A protein is well known as a myelin associated inhibitor of axonal
plasticity (Gonzenbach and Schwab, 2008), and has also been found to be expressed in
many CNS neurons (Wang et al., 2002c; Hunt et al., 2003; Buss et al., 2005). Mounting
evidence suggests that the Nogo-A protein may be a therapeutic target in several different
neurological diseases such as stroke and SCI. The overall idea is that by neutralizing
Nogo-A there will be enhanced axonal and dendritic plasticity, and this will allow the
CNS to modify its neural circuits in response to injury or disease and lead to recovery of
function.
For example, in a non-human primate model of SCI, adult Macaque monkeys
given a unilateral cervical spinal cord injury and treated with anti-Nogo-A
immunotherapy had improved recovery of hand dexterity and axonal compensatory
growth (Freund et al., 2006; Freund et al., 2007b; Freund et al., 2009). In rodent models
of stroke, adult and aged rats given a unilateral sensorimotor cortical stroke and treated
with anti-Nogo-A immunotherapy had improved skilled forelimb sensorimotor function
(Papadopoulos et al., 2002a; Markus et al., 2005a; Seymour et al., 2005a; Tsai et al.,
2007), and in adult rats the improvement correlated with axonal compensatory growth
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(Papadopoulos et al., 2002a; Seymour et al., 2005a) and dendritic plasticity in the
contralesional sensorimotor cortex (Papadopoulos et al., 2006).
Further experiments, including the studies described in this dissertation, show that
anti-Nogo-A immunotherapy may also be effective in treating cognitive impairments.
After lateral fluid percussion injury, rats treated with anti-Nogo-A immunotherapy had
improved performance on a spatial memory task (Lenzlinger et al., 2005a; Marklund et
al., 2007b). Another study showed recovery from a cortical injury causing severe neglect
after anti-Nogo-A immunotherapy. When the corpus callosum was then cut, the severe
neglect was again manifested, demonstrating that the contralateral cortex was involved in
the recovery induced by anti-Nogo-A immunotherapy (Brenneman et al., 2008b). The
work described in this dissertation provides further evidence that anti-Nogo-A
immunotherapy is an effective treatment for cognitive impairments after various types of
brain injury. This opens the possibility that anti-Nogo-A immunotherapy could be
effective in treating cognitive impairments caused by other etiologies such as
Alzheimer’s disease. Furthermore, the studies in this dissertation give support to an
earlier study that anti-Nogo-A immunotherapy is effective in aged subjects (Markus et
al., 2005b), which is important because stroke is much more prevalent in the aged human
population.
The studies in this dissertation also demonstrate that viral vector mediated RNA
interference is an effective way to decrease Nogo-A expression in neurons. Vector
mediated gene therapy against Nogo-A is a promising approach, but it has limitations to
be addressed including cell specificity of transduction, possible tissue damage at the
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injection site and possible host immune response. This approach may have more utility
for injection at the location of prior damage such as in SCI.
Anti-Nogo-A immunotherapy also has limitations to be addressed. Currently,
anti-Nogo-A immunotherapy has only been proven to be effective when delivered into
the cerebroventricular system, including the intrathecal route (Tsai et al., 2007).
However, intrathecal delivery could be a limiting factor for delivery to the very aged
population with multiple co-morbidities who are most likely to experience a stroke.
Therefore, development of an intravenous anti-Nogo-A immunotherapy is of great
importance.
Anti-Nogo-A immunotherapy is in phase I clinical trials for acute spinal cord
injury and clinical trials for stroke are currently in development. If the promise shown by
rodent and non-human primate pre-clinical studies is also realized in human trials then
anti-Nogo-A immunotherapy has the potential to make remarkable advances in the
treatment of neurological disease.

FUTURE DIRECTIONS
These experiments show that anti-Nogo-A immunotherapy improves performance
on a spatial memory task in aged rats after stroke. However, anti-Nogo-A immunotherapy
did not affect dendritic plasticity in the hippocampus, a brain area particularly important
for spatial memory. Further studies are needed to identify neuroanatomical correlates of
the improved performance in spatial memory after stroke and treatment with anti-Nogo-A
immunotherapy.
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One promising avenue to explore is axonal plasticity in the hippocampus. In
hippocampal slice cultures treatment with anti-Nogo-A antibodies increased axonal
regeneration/sprouting either in intact preparations or after cutting the Schaffer collaterals
(Craveiro et al., 2008a) or perforant pathway (Mingorance et al., 2004b). Therefore,
future studies should investigate axonal plasticity within the circuitry of the hippocampus
and in its efferents and afferents after stroke and treatment with anti-Nogo-A
immunotherapy.
Another promising avenue to explore is neuroanatomical plasticity within the
cholinergic system. Cholinergic axons have been shown to regenerate/sprout after
treatment with anti-Nogo-A antibodies in fibers innervating the sensorimotor cortex after
aspiration lesion and neocortical graft (Schulz et al., 1998), and in fibers innervating the
hippocampus after fimbria-fornix lesions (Cadelli and Schwab, 1991b). Furthermore,
disruption of the cholinergic system can cause impaired performance on the Morris water
maze (D'Hooge and De Deyn, 2001b). Therefore, future studies should investigate axonal
plasticity within the cholinergic system after stroke and treatment with anti-Nogo-A
immunotherapy.
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APPENDIX B: PILOT EXPERIMENTS
OPTIMIZATION OF MCAO IN FISCHER 344 RATS
Rationale
Stroke lesion size and location after MCAO in rats can vary depending upon the strain of
rat used due to differences in vasculature. For our stroke experiments we usually use
Long Evans black-hooded rats because reproducible stroke lesions to the sensorimotor
cortex with subcortical sparing result from MCAO with permanent ipsilateral carotid
occlusion and 60 minute contralateral carotid occlusion. However, aged rodent colonies
of Long Evans black-hooded rats are not maintained by the vendors, so it is very
expensive and time consuming to acquire aged Long Evans black-hooded rats. Our goal
for this experiment was to determine if reproducible stroke lesions to the sensorimotor
cortex could be accomplished in another rat strain. We chose the Fischer 344 strain
because the National Institute on Aging maintains an aged Fischer 344 rodent colony, and
these rats are readily available at a reasonable cost to researchers funded by the National
Institutes of Health, or the Department of Veterans Affairs.

Methods
Animal Subjects
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Subjects were aged male Fischer 344 rats (20-22
months of age at time of sacrifice).
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Stroke Surgery
MCAO was performed as described in chapter 3, except that ipsilateral and contralateral
carotid occlusions were varied.

TTC (2,3,5-triphenyl-2H-tetrazolium chloride) reaction
Rats were overdosed with pentobarbital (100 mg/kg, i.p.) and the brain was removed, and
cut into 2 mm coronal sections using a rat brain matrix on ice. The sections were then
incubated for 25 minutes at room temperature in 2% TTC (Sigma, St. Louis, MO, USA)
in phosphate buffered 0.9% saline, and then fixed in 4% paraformaldehyde.

Results
In Fischer 344 rats, MCAO without ipsi or contralateral carotid occlusion did not cause a
stroke lesion (App B Fig 1A,B). MCAO with permanent ipsilateral carotid occlusion and
30 or 60 minute contralateral carotid occlusion caused a stroke lesion to the sensorimotor
cortex with some minimal subcortical involvement (App B Fig 1C,D). MCAO with
permanent ipsilateral carotid occlusion and no contralateral carotid occlusion caused a
stroke lesion to the sensorimotor cortex and spared subcortical structures (App B Fig 1E).
However, when we repeated this procedure in another aged Fisher 344 rat, no stroke
lesion resulted (described in the next section of Appendix B).
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Middle Cerebral Artery Occlusion in Fischer 344 Aged Rats.

App. B Figure 1. Middle Cerebral Artery Occlusion in Fischer 344 Aged Rats. Thirty
minutes post-stroke, left MCAO and no carotid occlusion (A). One day post-stroke, right
MCAO and no carotid occlusion (B). Three days post-stroke, right sided stroke after
MCAO, permanent ipsilateral carotid occlusion and 30 minute contralateral carotid
occlusion, note minimal subcortical damage (C). One day post-stroke, left sided stroke
after MCAO, permanent ipsilateral carotid occlusion and 60 minute contralateral carotid
occlusion, note minimal subcortical damage (D). One day post-stroke, right sided stroke
after MCAO and permanent ipsilateral carotid occlusion and no contralateral carotid
occlusion (E). Scale Bar = 1 cm.
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Conclusion
This experiment demonstrates that in Fischer 344 aged rats induction of reproducible
sensorimotor cortical strokes requires MCAO with permanent ipsilateral carotid
occlusion and at least 30 minute contralateral carotid occlusion.
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APPENDIX B: PILOT EXPERIMENTS
ANTIBODY SPREAD AFTER INTRACEREBROVENTRICULAR INJECTION
Rationale
It has been demonstrated that after infusion of the 11C7 anti-Nogo-A antibody into the
lateral ventricle of adult rats after stroke the antibody spreads throughout the entire
neuroaxis (Weinmann et al., 2006). We sought to repeat this experiment in aged rats with
a MCAO.

Methods
Animal Subject
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Subject was one male Fischer 344 (21 months of age).

Stroke Surgery
MCAO on the right was performed as described in chapter 3 with permanent ipsilateral
carotid occlusion and no contralateral carotid occlusion.

Antibody Intracerebroventricular Infusion
Infusion of the 11C7 antibody was performed as described in chapter 3, except the
cannula was placed at coordinates 1.3 mm lateral (right), 3 mm posterior, and 3.8 mm
ventral (relative to bregma).
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Immunostaining
Three weeks post-stroke the rat was overdosed with pentobarbital (100 mg/kg,
intraperitoneal) and transcardially perfused with 0.9% saline and 10,000 U heparin/liter
followed by 4% paraformaldehyde. The brain and spinal cord was removed and
immersed whole in 4% paraformaldehyde for 1 hour, and then transferred to 30% sucrose
for four days. The brain and spinal cord was stored at -80º C until they were sectioned
coronally on a cryostat at 40 µm. Alternate free floating sections were selected for
immunostaining. Sections were blocked for 1 hour at room temperature with 10% normal
goat serum (NGS), and 0.25% Triton-X 100 (TX100) in 1x Tris buffered saline (TBS).
Next the sections were incubated overnight at 4º C with rabbit anti-mouse IgG1
(Invitrogen, Carlsbad, CA, USA) at 1:500 with 5% NGS and 0.25% TX100 in TBS. After
washing, sections were incubated for 1 hour at room temperature with biotin-XX goat
anti-rabbit IgG (Invitrogen), at 1:500 with 5% NGS and 0.25% TX100 in TBS. After
washing, sections were incubated for 1 hour at room temperature with streptavidin alexa
fluor 488 conjugate (Invitrogen), at 1:1000 with 5% NGS and 0.25% TX100 in TBS.
Next sections were washed and reacted with cupric sulfate for 15 minutes as described in
chapter 4 to reduce lipofuscin autofluorescence. Sections were then mounted to slides and
coverslipped with Fluoromount-G (Southern Biotech, Birmingham, AL, USA). Images
were acquired at 5x using a Leica fluorescent microscope.
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Results
Two occurrences made the results difficult to interpret. First, the cannula was placed too
far rostrally and ended up in the fimbria of the hippocampus instead of the right lateral
ventricle. Therefore, the antibody was being delivered to the parenchyma, rather than into
the cerebral spinal fluid. Second, the rat did not have a detectable stroke lesion resulting
from MCAO and permanent occlusion of the ipsilateral carotid artery. The 11C7
antibody was concentrated around the injection location in the fimbria and dorsal
hippocampus, but spread to other areas of the brain including the cortex (App B Fig 2).
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Spread of the 11C7 Antibody after Infusion into the Fimbria of the Hippocampus

App. B Figure 2. Spread of the 11C7 antibody to the right cortex after infusion.
11C7 is immunostained in the cortex and the external capsule. 5x objective, Scale
Bar=250 µm.

Conclusion
Due to the incorrect cannula placement the results of this experiment cannot show the
extent to which 11C7 can spread after infusion into the lateral ventricle. However, the
results do show that even with misplacement of the cannula, the antibody was able to
spread considerable distances, even bilaterally in the dorsal hippocampus. This
experiment also shows that stroke lesions in Fischer 344 rats are not consistent after

146
MCAO with permanent ipsilateral carotid occlusion and no contralateral carotid
occlusion, when taken together with the experiments described above in Appendix B.
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APPENDIX B: PILOT EXPERIMENTS
OPTIMIZE AAV2/8 HIPPOCAMPAL INJECTIONS IN AGED RATS
Rationale
We have previously injected AAV2/8 vectors carrying the EGFP transgene into the
cortex of neonatal rats (Pradhan, 2007), but we have not done so with aged animals. This
experiment was undertaken to optimize injection location and amount of AAV2/8 for
transduction of the aged rodent hippocampus.

Methods
Animal Subjects
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Subjects were 13 male Fischer 344 rats (20-23 months
of age at time of sacrifice).

Intracranial Injection Surgery
Intracranial injection surgeries were performed as described in chapter 4, except with
various injection locations and amounts. For pilot rats 1-8 we used vectors that had been
stored in the refrigerator for over a year and likely their titers had decreased from the titer
measured when they were prepared. The initial titers of these vectors were as follows:
AAV-EGFP 8×105 iu/ml, AAV-shLuciferase (Luc) 1.8×108 iu/ml, and AAV-shNogo856
3×107 iu/ml. For pilot rats 9-13 we used a freshly prepared batch of vectors with the
following titers: AAV-EGFP 2×109 iu/ml, and AAV-shNogo856 2×109 iu/ml Also the
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early surgeries were performed without the microinjection pump. Injection location,
amounts and any unique features for each rat are described in the results sections. On a
technical note, all injections before pilot rat 13 were done with metal hub (N) Hamilton
needles and luer tip (LT) syringes. We discovered that these needles can leak at the
junction between the needle and the syringe, and we feel that this explains some of the
variability in transduction in pilot rats 1-12. After discovering this, we began to use
removable needles (RN) and the RN syringes and had more consistent results as
described in the main experiment in chapter four.

Tissue Processing
Rats were overdosed with pentobarbital (100 mg/kg, intraperitoneal) and transcardially
perfused with 0.9% saline and 10,000 U heparin/liter followed by 4% paraformaldehyde.
The brains were removed and immersed whole in 4% paraformaldehyde for 1 hour, and
then transferred to 30% sucrose for three days. The brains were stored at -80º C until they
were sectioned coronally on a cryostat. Sections were washed and reacted with cupric
sulfate as described in chapter 4 to reduce lipofuscin autofluorescence. Sections were
then mounted to slides and coverslipped with Fluoromount-G (Southern Biotech,
Birmingham, AL, USA). Images were acquired using a Leica fluorescent microscope.
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Results
Rat 1
Rat 1 was injected with 6 µl of AAV-EGFP on each side of the hippocampus at
coordinates 2 mm lateral, 3.6 mm posterior, and 3.5 and 2.8 mm ventral (3 µl for each
depth), relative to bregma (Klein et al., 2006b). Two weeks later the rat was sacrificed.
The brain sections from this rat had a 45 minute cupric sulfate treatment to reduce
lipofuscin autofluorescence. We found that the injections were too far rostral and ventral
and transduced cells were located in the fimbria of the hippocampus.

App. B Figure 3. AAV-EGFP transduction in the fimbria of pilot rat 1. 10x
objective, Scale Bar=250 µm.

Rat 2
Rat 2 was injected with 6 µl in the left hippocampus and 2 µl in the right hippocampus
with AAV-shLuc also containing the EGFP transgene. On the left the coordinates were
1.5 mm lateral, 4.54, 5.34 and 6.55 mm posterior (2 µl for each location), and 2.5 mm
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ventral, relative to bregma. On the right the coordinates were 1.5 mm lateral, 4.54 and
5.34 posterior (1 µl for each location), and 2.5 mm ventral, relative to bregma. Two
weeks later the rat was sacrificed. We found that 15 minutes of Cupric Sulfate treatment
sufficient to significantly reduce the lipofuscin autofluorescence, and all further rat brains
were treated for 15 minutes. On the left injections were a bit too ventral, but there was
good transduction of hippocampal cells. On the right there was minimal transduction of
the hippocampus. Additionally, a planned third injection location on the right was not
completed because of rupture of a cerebral sinus, demonstrating that 1.5 mm lateral is too
close to the midline.

App. B Figure 4. AAV-shLuc transduction in the left dorsal hippocampus of pilot
rat 2. 5x objective, Scale Bar=250 µm.
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Rat 3
Rat 3 was injected with 4 µl in the left hippocampus and 2 µl in the right hippocampus
with AAV-shLuc. On the left the coordinates were 2.0 mm lateral, 4.8 and 5.8 mm
posterior (2 µl for each location), and 2.5 mm ventral, relative to bregma. On the right the
coordinates were 2.0 mm lateral, 4.54 and 5.34 posterior (1 µl for each location), and 2.5
mm ventral, relative to bregma. Two weeks later the rat was sacrificed. Bilaterally in the
hippocampus transduction was minimal, but the few transduced cells were in the middle
of the dorsal hippocampus.

Rat 4
Rat 4 was injected with 6 µl of AAV-shNogo856 on each side of the hippocampus at
coordinates 2 mm lateral, 4.5, 5.3 and 6.1 mm posterior, and 2.0 and 2.5 mm ventral (1 µl
for each depth), relative to bregma. Two weeks later the rat was sacrificed. The injections
appeared to be a bit too dorsal causing neocortical transduction, and did not spread far
enough lateral in the dorsal hippocampus.
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App. B Figure 5. AAV-shNogo856 transduction in the right dorsal hippocampus of
pilot rat 4. 5x objective, Scale Bar=250 µm.
Rat 5
Rat 5 was injected with 6 µl of AAV-shNogo856 on the left side of the hippocampus at
coordinates 2 mm lateral, 4.5, 5.3 and 6.1 mm posterior, and 2.0 and 2.5 mm ventral (1 µl
for each depth), relative to bregma. Two weeks later the rat was sacrificed. Transduction
was minimal, but the few transduced cells were located in the dorsal hippocampus.

Rat 6
Rat 6 was injected with 6 µl of AAV-shNogo856 on each side of the hippocampus at
coordinates 2 and 2.75 mm lateral, 5 and 5.6 mm posterior (more posterior location is
also the more lateral), and 2.5 and 2.3 mm ventral (1.5 µl for each depth), relative to
bregma. Two weeks later the rat was sacrificed. Injections were too dorsal on the right
and too ventral on the left.
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App. B Figure 6. AAV-shNogo856 transduction in the left dorsal hippocampus of
pilot rat 6. Note that on this side the injections were too ventral causing transduction in
the dentate gyrus, but not in CA1. 5x objective, Scale Bar=250 µm.

Rat 7
Rat 7 was injected with 6 µl of AAV-shNogo856 on the right side of the hippocampus at
coordinates 2 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm ventral (3 µl for each
depth), relative to bregma. Two weeks later the rat was sacrificed. Transduction was not
far enough ventral or lateral. We found bilateral transduction from this unilateral
injection of vector.

Rat 8
Rat 8 was injected with 6 µl of AAV-Luc on each side of the hippocampus at coordinates
2 and 2.75 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm ventral (1.5 µl for each
depth), relative to bregma. Two weeks later the rat was sacrificed. The injection locations
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were within the dorsal hippocampus and the injections caused transduction of many
hippocampal cells.

Rats 9 and 10
Rats 9 and 10 were injected with 6 µl of AAV-EGFP on each side of the hippocampus at
coordinates 2 and 2.75 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm ventral (1.5 µl
for each depth), relative to bregma. We began using the microinjection pump with pilot
rat 10. Four weeks later the rats were sacrificed. Cells were transduced in the dorsal
hippocampus including CA1 pyramidal cells.

App. B Figure 7. AAV-EGFP transduction in the dorsal hippocampus of pilot rat 9.
10x objective, Scale Bar=250 µm.

Rats 11 and 12
Rats 11 and 12 were injected with 6 µl of AAV-shNogo856 on each side of the
hippocampus at coordinates 2 and 2.75 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm
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ventral (1.5 µl for each depth), relative to bregma. Four weeks later the rats were
sacrificed. Transduction was very minimal, and this is the point at which we realized that
the virus was leaking at the junction of the metal hub needle and syringe.

Rat 13
Rat 13 was injected with 3 µl of AAV-shNogo856 on each side of the hippocampus at
coordinates 2.35 mm lateral, 5.3 mm posterior, and 2.5 and 2.3 mm ventral (1.5 µl for
each depth), relative to bregma. One week later the rats were sacrificed. Cells were
transduced in the dorsal hippocampus including CA1 pyramidal cells.

App. B Figure 8. AAV-shNogo856 transduction in the dorsal hippocampus of pilot
rat 13. 10x objective, Scale Bar=250 µm.
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Conclusion
These pilot experiments allowed us to identify and correct several technical difficulties
with injection of AAV into the hippocampus of aged rats. First, we had to adjust our
injection coordinates due to the different strain and age of the rats. We also discovered
that some types of Hamilton needles can leak at the junction between the needle and the
syringe, and this probably caused some of the inconsistencies in our pilot rat injections.
In retrospect, we now know that the transduction we saw during the pilot rat experiments
was much less than what we saw in the main experiments described in chapter 4. We feel
this was due to the leaking needles, and lower titers of the vectors we used for pilot rats
1-8.
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APPENDIX B: PILOT EXPERIMENTS
BRAIN PUNCHING AND WESTERN BLOT FOR NOGO-A
Rationale
We sought to determine whether we could detect the Nogo-A protein by western blot in
the different subregions of the hippocampus.

Methods
Animal Subjects
Experiments were approved by the Institutional Animal Care and Use Committee of
Hines Veterans Affairs Hospital. Subjects were 2 adult female Long Evans black-hooded
rats.

Tissue Preparation
Rats were overdosed with pentobarbital (100 mg/kg, i.p.) and the brain was removed and
rinsed in ice-cold saline, and cut into 1 mm coronal sections using a rat brain matrix on
ice. The sections were placed on glass slide and the slide was placed on dry ice. A brain
punch tissue set (The Vibratome Company, St. Louis, MO, USA), was used to take tissue
punches from the subregions of the hippocampus (CA1, CA3 and dentate gyrus). For rat
1 we used a punch with a larger internal diameter than what we used for rat 2, and due to
the larger size for rat 1 more white matter was included in the punched area. Tissue
samples were placed in eppendorf tubes and placed on dry ice, until they were placed in a
-80º C freezer for storage.
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Immunoblot
Proteins from tissue homogenates from different subregions of the hippocampus were
separated by Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDSPAGE) (4-12% gradient gel) and then blotted onto a polyvinylidene difluoride (PVDF)
membrane. The membrane was then blocked in 5% non-fat milk in 1x TBS/.05%
TWEEN 20 (TBST) for 20 minutes, and then incubated overnight at 4º C with the
primary antibody (11C7) at 1:20,000 in 5% non-fat milk in TBST. The membrane was
then washed in TBST and then incubated with the secondary antibody (goat anti-Mouse
IgG horseradish peroxidase (HRP)-conjugated, Pierce, Rockford, IL, USA) at 1:10,000
in 5% non-fat milk in TBST for 2 hours. Then the blot was treated with SuperSignal
West Pico Chemiluminescent Substrate (Pierce) for 30 seconds. The blot was
developed with Kodak BioMax light films and Kodak M35A X-OMAT processor.

Results
Nogo-A protein expression was detected in both rats in CA1 and in the dentate gyrus
(App B Fig 9). Samples from CA3 were not analyzed. Rat 1 appeared to have a higher
expression of Nogo-A in CA1 and the dentate gyrus. This may be due to white matter
being included in the samples from rat 1.

159
kDa

← Nogo-A

App. B Figure 9. Nogo-A expression in the hippocampus of adult female rats.

Conclusion
Larger punch sizes were used for rat 1, and the tissue was not very well mounted and
frozen, thus there may have been white matter and other brain regions included in the
punches. For the second rat we were able to improve our technique by using paint
brushes to mount the sections before freezing them and by using smaller punch sizes.
The lower level of Nogo-A protein expression in rat 2 may reflect lower contamination of
the punches by white matter. The lack of degradation products suggests that using cold
saline to rinse the brain and freezing the sections to slides with dry ice worked well to
prevent protein degradation. Further studies may be able to differentiate differing NogoA protein expression in the different subregions of the hippocampus.
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